doi,study_id,author,year,year_date,country,country_economic_category,country_economic_category1,study_design,number_of_patients,inclusion_criteria,exclusion_criteria,extracorporeal,renal_function,patient_characteristics,patient_characteristics1,patient_characteristics2,patient_characteristics3,patient_characteristics4,other_patient_groups_studied,samples_used,other_samples,betalactam_studied,abx_cat,other_antimicrobials,quantification_method,modelling_software,compartments,model_evaluation_process,covariate_identification,covariate_testing_method,method_for_PTA,covariates_reported
https://dx.doi.org/10.1128/AAC.01543-15,1,Abdul-Aziz,2016,2016-01-01,Malaysia,Upper-middle-income,Middle-income,prospective PK study,12,adult (≥18 years old) ICU patients and were prescribed doripenem for the treatment of sepsis (defined as presumed or confirmed infection with systemic inflammatory response syndrome manifesting in the previous 48 h),"required any form of extracorporeal renal support, were pregnant or lactating mothers, or were known or presumed to be allergic to doripenem or any of the carbapenem antibiotics",no,normal,"sepsis, VAP",sepsis,VAP,NA,NA,no,plasma,no,doripenem,carbapenem,no,HPLC,NONMEM 7.3,2,"nonparametric bootstrap, VPC",biological plausibility,"stepwise forward inclusion, backward elimination, scatter plots",Monte Carlo,yes
https://dx.doi.org/10.1128/AAC.00745-20,2,Al-Shaer,2020,2020-01-01,USA,High-income,High-income,retrospective PK study,230,"paediatric dataset: ages of 2 months and 18 years; adult dataset: 18 years of age or older, received cefepime, had cefepime concentrations reported as part of routine clinical care, and were admitted to the medical, surgical, cardiac, or neurological ICU between 2016 and 2018","paediatric dataset: allergic to beta-lactam antibiotics or if they had central nervous system involvement, human immunodeficiency virus infection, cystic fibrosis, endocarditis, lung abscess, osteomyelitis, severe burns (≥20% full thickness), an infected prosthesis, an absolute granulocyte count of <500/mm3, or a serum creatinine level of >2 mg/dl; adult dataset: receiving renal replacement therapy",no,normal,general ICU,general ICU,NA,NA,NA,yes,plasma,no,cefepime,cephalosporin,no,"HPLC, LC-MS/MS",Pmetrics 1.5.2,2,"AIC, coefficient of determination of observed versus predicted plots for both population and Bayesian models, imprecision, bias",NA,stepwise forward inclusion,Monte Carlo,yes
https://dx.doi.org/10.1128/AAC.00144-21,3,Al-Shaer,2021,2021-01-01,USA,High-income,High-income,prospective PK study,10,"≥18 years old, were admitted to the ICU, and received cefepime 2 g i.v. every 8 h as a 4-h infusion while on CVVH or CVVHD","pregnancy, cystic fibrosis, incarceration, admission for burns, and unmeasured or >400 ml of urine output in the last 24 h",RRT,impaired,CRRT,CRRT,NA,NA,NA,no,plasma,"predialyzer serum, postdialyzer serum, and effluent samples",cefepime,cephalosporin,no,HPLC,Pmetrics 1.9.7,5,"AIC, highest coefficient of determination of observed versus predicted plots for both population and Bayesian, lowest imprecision, lowest bias",NA,stepwise forward inclusion,Monte Carlo,yes
https://dx.doi.org/10.1128/AAC.01611-21,4,Al-Shaer,2022,2022-01-01,USA,High-income,High-income,retrospective PK study,125,"dataset 1: adult ICU patients who received cefepime 2 g IV every 8 h via a 4-h infusion while on CVVH or CVVHD; dataset 2: adult patients admitted to the medical or surgical ICU, receiving CVVH or CVVHD, and received cefepime 2 g IV over 30 min every 8 h; dataset 3: ICU patients admitted to UF Health between 2016 and 2021, on CRRT, received cefepime therapy, and had cefepime plasma concentration measured","dataset 1: pregnancy, cystic fibrosis, incarceration, admission for burns, and unmeasured or >400 mL of urine output in the last 24 h; dataset 2: pregnancy and incarceration; dataset 3: CRRT started after measuring cefepime concentration",RRT,impaired,CRRT,CRRT,NA,NA,NA,no,plasma,"predialyzer serum, postdialyzer serum, and effluent samples",cefepime,cephalosporin,no,"HPLC, LC-MS/MS",Pmetrics 1.9.7,5,"AIC, highest coefficient of determination of observed versus predicted concentration plots, lowest imprecision, lowest bias",NA,NA,NA,no
https://dx.doi.org/10.1128/AAC.00531-16,5,Alobaid,2016,2016-01-01,Australia,High-income,High-income,prospective PK study,19,"age of ≥18 years, receiving meropenem (prophylaxis or treatment), and body mass index (BMI) of ≥18.5 kg/m2","patients on renal replacement therapy, pregnant women, actively bleeding patients, patients with HIV or hepatitis",no,normal,obesity,obesity,NA,NA,NA,no,plasma,no,meropenem,carbapenem,no,HPLC-UV,Pmetrics,2,"VPC, coefficient of determination of linear regression of observed-predicted values, log likelihood values, bias, imprecision",biological plausibility,"stepwise forward inclusion, LLR",Monte Carlo,yes
https://dx.doi.org/10.1128/AAC.01276-16,6,Alobaid,2017,2017-01-01,Australia,High-income,High-income,prospective PK study,37,"age of ≥18 years, treatment with piperacillin, BMI of ≥18.5 kg/m2","renal replacement therapy (RRT), pregnancy for women, active bleeding, HIV infection or hepatitis",no,normal,obesity,obesity,NA,NA,NA,no,plasma,no,piperacillin,penicillin,no,UHPLC-MS/MS,Pmetrics,2,"visual inspection of scatter plots, coefficient of determination of the linear regression of the observed-predicted values, log likelihood values, imprecision, bias, bootstrapping, VPC",NA,"bootstrapping, VPC",Monte Carlo,yes
https://dx.doi.org/10.1128/aac.01312-22,7,An,2023,2023-01-01,USA,High-income,High-income,prospective PK study,130,adult ICU patients prescribed intravenous meropenem as the standard of care,"patients who were on intermittent dialysis or extracorporeal membrane oxygenation, receiving probenecid, or who were pregnant at the time of enrollment",no,normal,general ICU,general ICU,NA,NA,NA,no,plasma,no,meropenem,carbapenem,no,LC-MS/MS,NONMEM 7.4.3,1,"objective function values, precision of the estimated parameters, goodness-of-fit plots, AIC, VPC, LRT",biological plausibility,"stepwise forward inclusion, backward elimination, OFV",Monte Carlo,yes
https://dx.doi.org/10.1093/jac/dkt304,8,Asin-Prieto,2014,2014-01-01,Spain,High-income,High-income,prospective PK study,16,aged >18 years and needing to be treated with continuous venovenous haemofiltration for at least 20 h,NA,RRT,impaired,CRRT,CRRT,NA,NA,NA,no,plasma,no,piperacillin,penicillin,tazobactam,HPLC–UV,NONMEM 7.2,2,"goodness-of-fit, bootstrapping, VPC",NA,"stepwise forward inclusion, backward elimination, goodness-of-fit plots",Monte Carlo,yes
https://dx.doi.org/10.1002/phar.2766,9,Barreto,2023,2023-01-01,USA,High-income,High-income,prospective PK study,100,treated with cefepime at a stable dose and interval,"exposure to cefepime within the 4-days prior to the study course, received greater than one dose of cefepime prior to ICU admission, had acute kidney injury stage II or higher, were on kidney replacement therapy, or were cannulated for extracorporeal membrane oxygenation at the time of beta-lactam initiation, patient did not authorize their medical records to be used for research",no,normal,general ICU,general ICU,NA,NA,NA,no,plasma,no,cefepime,cephalosporin,no,IDMS,Monolix 2020R1,1,"BIC, goodness-of-fit, between subject variability of population estimates",biological plausibility,stepwise fashion,NA,yes
https://dx.doi.org/10.1093/jac/dkaa362,10,Bastida,2020,2020-01-01,Spain,High-income,High-income,prospective PK study,54,"presence of cirrhosis, age ≥18 years and clinical indication for treatment with meropenem","HIV infection, advanced neoplasm (except for hepatocellular carcinoma under the Milan criteria) and renal replacement therapy",no,unclear,decompensated liver disease,liver failure,NA,NA,NA,no,plasma,no,meropenem,carbapenem,no,UHPLC,NONMEM 7.3,1,"clinical plausibility, significant decreases in objective function value, bootstrapping, VPC",biological plausibility,"scatter plots, distribution of residuals, Bayesian shrinkage",Monte Carlo,yes
https://dx.doi.org/10.1186/s13054-020-2763-4,11,Benitez-Cano,2020,2020-01-01,Spain,High-income,High-income,prospective randomised PK trial,31,"age ≥ 18 years, diagnosis of nosocomial pneumonia and risk factors for multidrug-resistant (MDR) pathogens, and GFR ≥ 50 mL/min/1.73 m2","allergy to β-lactams, previous use of carbapenems within 15 days, GFR < 50 mL/min/1.73 m2, severely impaired liver function (child-pugh C), obesity (BMI>30), pregnancy, life expectancy < 3 days, and colonization with pathogens known to be resistant to meropenem",no,normal,pneumonia,pneumonia,NA,NA,NA,no,plasma,epithelial lining fluid,meropenem,carbapenem,no,HPLC,Pmetrics,3,"VPC, linear regression, bias, imprecision",NA,stepwise linear regression,Monte Carlo,yes
https://dx.doi.org/10.1345/aph.1R789,12,Bhalodi,2013,2013-01-01,USA,High-income,High-income,prospective PK study,25,received at least 3 doses of doripenem for any infection between February 2010 and March 2012,"poor candidates for blood collection, required hemodialysis or a continuous renal replacement therapy, or were diagnosed with cystic fibrosis",no,normal,general ICU and non-ICU,general ICU,NA,NA,NA,yes,serum,no,doripenem,carbapenem,no,HPLC,BigNPAG,2,"Bayesian estimates, bias, imprecision, r2",NA,NA,Monte Carlo,yes
https://dx.doi.org/10.1128/aac.00845-22,13,Boonpeng,2022,2022-01-01,Thailand,Upper-middle-income,Middle-income,prospective PK study,52,"age of ≥18 years, confirmed or suspected bacterial infection, intravenous meropenem therapy, hospitalization in a medical or surgical ICU","requirement of renal replacement therapy, pregnancy or breastfeeding, a history of meropenem hypersensitivity",no,normal,general ICU,general ICU,NA,NA,NA,no,plasma,no,meropenem,carbapenem,no,HPLC,"NONMEM 7.4.3, Pirana 3.0.0",2,"OFV, AIC, parameter precision, visual inspection of various goodness-of-fit plots, bootstrapping, VPC",NA,"stepwise forward inclusion, backward elimination",Monte Carlo,yes
https://dx.doi.org/10.1186/s13054-018-1940-1,14,Braune,2018,2018-01-01,Germany,High-income,High-income,prospective PK study,19,aged > 18 years treated with meropenem and receiving SLED during daytime,NA,RRT,impaired,SLED,CRRT,NA,NA,NA,no,serum,no,meropenem,carbapenem,no,HPLC-UV,Pmetrics,2,"coefficient of determination of the linear regression, bias, reduction in the log-likelihood, goodness-of-fit plots, imprecision, VPC, normalised prediction distribution errors",biological plausibility,stepwise forward inclusion,Monte Carlo,yes
https://dx.doi.org/10.1016/j.ijid.2020.01.010,15,Bue,2020,2020-01-01,Denmark,High-income,High-income,prospective PK study,10,patients treated with intravenous piperacillin/tazobactam (4 g/0.5 g) q8h given as an IA over 3 min and requiring CRRT,"pregnancy, platelets below 5 × 109/l, international normalized ratio (INR) above 5, known allergy to benzylpenicillin or piperacillin, lactate >4 mmol/l, and the need for noradrenalin >0.50 μg/kg/min or the equivalent doses of vasopressors",RRT,impaired,CRRT,CRRT,NA,NA,NA,no,plasma,subcutaneous tissue,piperacillin,penicillin,tazobactam,UHPLC,"NONMEM 7.4.3, Pirana",2,"statistical goodness-of-fit, graphical evaluation of residual diagnostic plots, VPC, plausibility, imprecision","graphical evaluation, LRT","stepwise forward inclusion, backward elimination",Monte Carlo,yes
https://dx.doi.org/10.3390/antibiotics10060612,16,Buning,2021,2021-01-01,Netherlands,High-income,High-income,retrospective PK study,96,"aged ≥18 years treated with IV ceftazidime for a proven or suspected clinically relevant P. aeruginosa infection, and with at least one detectable ceftazidime serum concentration available during the course of therapy",cystic fibrosis,no,unclear,general ICU,general ICU,NA,NA,NA,no,serum,no,ceftazidime,cephalosporin,no,LC-MS/MS,NONMEM 7.1.2,1,"VPC, bootstrapping, Bayesian estimates, LRT",NA,stepwise forward inclusion,Monte Carlo,yes
https://dx.doi.org/10.1093/jac/dky370,17,Burger,2018,2018-01-01,Switzerland,High-income,High-income,prospective PK study,86,"prospectively enrolled in a therapeutic drug monitoring study, which aimed to assess the clinical utility of measuring antibiotic blood concentrations (n = 30) or were included in the institutional TDM programme (n = 56)",NA,RRT,impaired,CRRT,CRRT,NA,NA,NA,no,plasma,no,meropenem,carbapenem,no,"UPLC-MS, HPLC-UV","NONMEM 7.2, Xpose4",2,"bootstrapping, VPC, external model validation dataset",NA,"stepwise forward inclusion, backward elimination",Monte Carlo,yes
https://dx.doi.org/10.1093/jac/dkl485,18,Burkhardt,2007,2007-01-01,Germany,High-income,High-income,prospective PK study,17,"critically ill patients treated with ertapenem for early-onset VAP (≤4 days of mechanical ventilation). VAP diagnosis based on a new and persistent infiltrate on the chest radiograph, and two of the following three criteria: fever > 38.3°C, WBC count > 12 000 cells/mm3, and/or purulent tracheobronchial secretions","child-bearing potential, pregnancy, lactation, a severely immunocompromised status, use of any antibacterial agent 4 weeks before study entry, a concomitant disease that may interfere with the course of the study, severe hepatic and renal impairment (CLCREA < 30 mL/min), drug or alcohol abuse in medical history, allergy to β-lactam antibiotics",no,normal,VAP,VAP,NA,NA,NA,no,plasma,no,ertapenem,carbapenem,no,HPLC,NONMEM 5,2,"AIC, Schwartz criteria",NA,"stepwise forward inclusion, likelihood ratio test, backward deletion",NA,yes
https://dx.doi.org/10.1093/jac/dkt240,19,Carlier,2013,2013-01-01,Belgium,High-income,High-income,prospective PK study,13,admitted to the ICU and prescribed amoxicillin/clavulanic acid,"<18 years of age, a haematocrit of <21%, absence of an arterial catheter or need for renal replacement therapy",no,normal,no,general ICU,NA,NA,NA,no,plasma,no,amoxicillin,penicillin,clavulanic acid,UHPLC-MS/MS,NONMEM 6.1,2,"OFV, log-likelihood ratios, bootstrapping",NA,"stepwise forward inclusion, backward deletion",NA,yes
https://dx.doi.org/10.1093/jac/dku195,20,Carlier,2014,2014-01-01,Belgium,High-income,High-income,prospective PK study,20,admitted to the ICU and prescribed cefuroxime,"<18 years of age, a haematocrit of <21%, absence of an arterial catheter or need for renal replacement therapy",no,normal,no,general ICU,NA,NA,NA,no,plasma,no,cefuroxime,cephalosporin,no,UHPLC-MS/MS,NONMEM 7.3,2,"OFV, log-likelihood ratios, bootstrapping",NA,stepwise forward inclusion,Monte Carlo,yes
https://dx.doi.org/10.1093/jac/dky489,21,Chauzy,2019,2019-01-01,France,High-income,High-income,prospective PK study,11,hospitalized in the neurosurgery ICU with an EVD and with or without suspected meningitis/ventriculitis (> 5 leucocytes/mm3 and/or positive direct examination or positive culture),NA,no,unclear,meningitis/ventriculitis,CNS infection,NA,NA,NA,no,plasma,CSF,ceftaroline,cephalosporin,no,LC-MS/MS,NONMEM 7.4,2,VPC,NA,"stepwise forward inclusion, backward elimination",NA,yes
https://dx.doi.org/10.1093/jac/dkac299,22,Chauzy,2022,2022-01-01,France,High-income,High-income,prospective PK study,18,"ICU patients aged ≥ 18 years, mechanically ventilated, presenting early-onset (i.e. during the 7 days following hospital admission) pneumonia caused by Gram-positive and/or Gram-negative bacteria and a creatinine clearance more than 80 mL/min/1.73 m2 estimated by the MDRD formula","renal impairment (measured urinary CLCR <80 mL/min/1.73 m2), one or more risk factors of MDR bacteria, septic shock, BMI >40 kg/m2, diuretic treatment, ceftaroline contraindications and suspicion or confirmation of pneumonia due to ceftaroline-resistant bacteria",no,augmented,"pneumonia, augmented renal clearance",pneumonia,ARC,NA,NA,no,plasma,no,ceftaroline,cephalosporin,no,LC–MS/MS,NONMEM 7.4,2,"improvement of diagnostic plots, OFV, VPC, shrinkage",NA,"stepwise forward inclusion, backward elimination",Monte Carlo,yes
https://dx.doi.org/10.1002/jcph.196,23,Cheatham,2014,2014-01-01,USA,High-income,High-income,prospective PK study,9,"adult patients who were hospitalized in an intensive care unit, body mass index ≥ 40 kg/m2, antimicrobial therapy for a suspected or documented bacterial infection, central venous access, and an estimated creatinine clearance ≥ 50 mL/min","history of allergy to carbapenems, pregnancy, undergoing dialysis of any type, and hepatic dysfunction defined as serum bilirubin and alanine aminotransferase levels above the normal upper limit by factors of ≥2 and ≥4, respectively",no,normal,obesity,obesity,NA,NA,NA,no,serum,no,meropenem,carbapenem,no,HPLC,Boomer 3.3.6,2,visual inspection,NA,linear regression,Monte Carlo,yes
https://dx.doi.org/10.1128/AAC.00385-20,24,Chen,2020,2020-01-01,China,Upper-middle-income,Middle-income,retrospective PK study,247,"patients ≥18 years old; sex (male and female); patients who were administered imipenem after clinical diagnosis; patients without additional lifestyle risk factors, such as smoking; patients with or without ECMO",blood sampling was not available at steady state after 4 doses of imipenem and/or all of the collected concentrations were below the lower limit of quantitation (LLOQ) and/or if patient before ECMO withdrawal,ECMO,unclear,ECMO,ECMO,NA,NA,NA,yes,plasma,no,imipenem,carbapenem,no,UPLC-MS/MS,NONMEM 7.2,2,"VPC, goodness-of-fit plots",NA,"stepwise forward inclusion, backward elimination, likelihood ratio test",Monte Carlo,yes
https://dx.doi.org/10.1128/AAC.01438-21,25,Cheng,2021,2021-01-01,International,High-income,High-income,prospective PK study,27,ICU patients aged between 18 and 90 years old who were receiving piperacillin and tazobactam while undergoing ECMO for respiratory and/or cardiac dysfunction,"known allergy to the study drug, pregnant, bilirubin >150 μmol/liter, ongoing massive blood transfusion (>50% blood volume) in the preceding 8 hours, therapeutic plasma exchange in the preceding 24 hours","ECMO, RRT",impaired,ECMO,ECMO,NA,NA,NA,no,plasma,no,piperacillin,penicillin,tazobactam,UHPLC-MS/MS,Pmetrics,2,"VPC, normalized prediction distribution errors, R2",biological plausibility,"stepwise forward inclusion, log likelihood, linear regression, backward deletion",Monte Carlo,yes
https://dx.doi.org/10.1016/j.ijantimicag.2021.106466,26,Cheng,2021,2021-01-01,International,High-income,High-income,prospective PK study,6,"patients aged between 18–90 years, hospitalised in ICU and who were receiving cefepime whilst undergoing ECMO for respiratory and/or cardiac dysfunction","known allergy to the study drug, pregnant, bilirubin > 150 µmol/L, ongoing massive blood transfusion (> 50% blood volume) in the preceding 8 hours, therapeutic plasma exchange in the preceding 24 hours",ECMO,unclear,ECMO,ECMO,NA,NA,NA,no,plasma,no,cefepime,cephalosporin,no,HPLC-PDA,Pmetrics,2,"VPC, normalized prediction distribution errors, R2",NA,"stepwise forward inclusion, log likelihood, linear regression, backward deletion",Monte Carlo,yes
https://dx.doi.org/10.1007/s40262-021-01106-x,27,Cheng,2022,2022-01-01,International,High-income,High-income,prospective PK study,14,ICU patients aged 18–90 years who were receiving ceftriaxone whilst undergoing ECMO for respiratory and/or cardiac dysfunction,"known allergy to the study drug, pregnant, bilirubin > 150 µmol/L, ongoing massive blood transfusion (> 50% blood volume) in the preceding 8 h, therapeutic plasma exchange in the preceding 24 h","ECMO, RRT",impaired,ECMO,ECMO,NA,NA,NA,no,plasma,no,ceftriaxone,cephalosporin,no,UHPLC-MS/MS,Pmetrics,2,"R2, bias, log-likelihood ratio, imprecision, BIC, AIC, VPC",biological plausibility,"stepwise forward inclusion, log likelihood, linear regression, backward deletion",Monte Carlo,yes
https://dx.doi.org/10.1177/1060028016676831,28,Chung,2017,2017-01-01,USA,High-income,High-income,prospective PK study,20,adult patients 18 to 65 years of age who were obese (BMI ≥ 40 kg/m2 or TBW ≥ 45.5 kg over their ideal body weight [IBW]) and hospitalized in an ICU or non-ICU,"documented allergy to any β-lactam antibiotic, history of drug or alcohol abuse, history of any seizure disorder, acute or chronic renal failure, renal replacement therapy of any type, or hepatic dysfunction defined as serum bilirubin and alanine aminotransferase concentrations ≥2 and ≥4 times the upper normal limit, respectively",no,normal,obesity,obesity,NA,NA,NA,yes,serum,no,doripenem,carbapenem,no,UPLC-MS/MS,NONMEM 7.4,2,"goodness-of-fit plots, AIC, OFV, visual inspection",NA,"stepwise forward inclusion, backward elimination",Monte Carlo,yes
https://dx.doi.org/10.3389/fphar.2021.781892,29,Cojutti,2021,2021-01-01,Italy,High-income,High-income,retrospective PK study,74,critically ill patients who were admitted to ICU and received continuous infusion meropenem for empirical or targeted treatment of Gram-negative-related infections,"absence of critical illness, meropenem administration by extended or intermittent infusion, blood sampling inconsistency, and application of renal replacement therapy",no,normal,general ICU,general ICU,NA,NA,NA,no,plasma,no,meropenem,carbapenem,no,LC–MS/MS,Pmetrics,1,"OFV, AIC, BIC",biological plausibility,"stepwise forward inclusion, backward elimination",Monte Carlo,yes
https://dx.doi.org/10.1111/j.1365-2125.2007.02857.x,30,Conil,2007,2007-01-01,France,High-income,High-income,prospective PK study,50,ICU burns patients in the secondary phase of their burn injuries with local infections or sepsis (empirically or targeted) prescribed ceftazidime,allergy to ceftazidime,no,unclear,burns,burns,NA,NA,NA,no,serum,no,ceftazidime,cephalosporin,no,HPLC,"NONMEM, Visual-NM",2,"bias, AIC, imprecision, OFV, Bayesian estimator",NA,structural model,NA,yes
https://dx.doi.org/10.1111/bcp.12435,31,Couffignal,2014,2014-01-01,France,High-income,High-income,prospective PK study,63,male or female over 18 years of age; use of mechanical ventilation for >48 h; clinical suspicion of VAP (new or persistent radiological infiltrate and one of the following criteria: purulent tracheal aspiration or temperature ≥ 38.3°C or leucocytosis >10 000 ml−1); VAP with high risk of multiresistant bacteria (at least 6 days of mechanical ventilation or antibiotic treatment within 15 days),time between diagnosis and first antibiotic therapy ≥24 h; expected death within 48 h; creatinine clearance <10 ml min−1 or renal replacement therapy,no,normal,VAP,VAP,NA,NA,NA,no,plasma,no,imipenem,carbapenem,no,HPLC,Monolix 4.1.2,2,"goodness-of-fit plots, VPC, normalized prediction distribution error",previously published covariates,"stepwise forward inclusion, backward elimination, BIC, bootstrapping",Monte Carlo,yes
https://dx.doi.org/10.1007/s00134-010-2105-0,32,Crandon,2011,2011-01-01,USA,High-income,High-income,prospective PK study,26,at least 18 years of age and had received at least 3 consecutive doses of meropenem,deemed poor candidates for blood collection or required hemodialysis during meropenem therapy,no,unclear,general ICU,general ICU,NA,NA,NA,no,serum,no,meropenem,carbapenem,no,HPLC,NA,2,goodness-of-fit plots,NA,NA,Monte Carlo,yes
https://dx.doi.org/10.1093/jac/dkm467,33,De Jongh,2008,2008-01-01,Belgium,High-income,High-income,prospective randomised PK trial,17,"(i) a high probability of infection from nosocomial origin [body temperature >38 or <35.5°C not induced by external factors; leucocytosis or leucopenia; one or several suspected infection foci (based on X-ray pathognomonic image, purulent sputum, white blood cells in urine, or other accepted clinical sign)]; and (ii) no suspicion of an infection by Pseudomonas spp. or another temocillin-resistant bacteria","(i) age <18 or >75 years; (ii) patient's weight <50 or >100 kg; (iii) renal insufficiency (estimated clearance <45 mL/min); (iv) haemodialysis; (v) estimated survival <5 days; (vi) documentation of temocillin-resistant organism; (vii) meningitis or other proven infections of the CNS; (viii) IgE-mediated allergy to penicillins; (ix) severe granulocytopenia (<500 polymorphonuclear leucocytes/mm3); (x) pregnancy; (xi) patients having participated in another study <30 days before; and (xii) retrospectively, marked deterioration of the renal function during the study period",no,normal,pneumonia,pneumonia,NA,NA,NA,no,serum,no,temocillin,penicillin,no,HPLC,WinNonMix,1,NA,NA,NA,Monte Carlo,no
https://dx.doi.org/10.1007/s40262-020-00859-1,34,de Velde,2020,2020-01-01,Switzerland,High-income,High-income,retrospective PK study,26,suspected or documented severe bacterial infection and age 18–60 years,"eGFR < 60 mL/min (measured by the Cockcroft–Gault [CG] equation [25]), body mass index < 18 or > 30 kg/m2, and pregnancy",no,normal,severe bacterial infection,severe bacterial infection,NA,NA,NA,no,plasma,no,imipenem,carbapenem,cilastatin,HPLC-UV,"NONMEM 7.2, Pmetrics",2,"OFV, goodness-of-fit plots, VPC",NA,"stepwise forward inclusion, backward elimination",Monte Carlo,yes
https://dx.doi.org/10.1016/j.clinbiochem.2012.03.030,35,Delattre,2012,2012-01-01,Belgium,High-income,High-income,prospective PK study,88,ICU patients diagnosed with severe sepsis or septicshock at their ICU admission or during their ICU stay. Severe sepsis and septic shock were defined according to standard criteria,"(i) age under 18 years or over 90 years, (ii) pregnancy or lactation, (iii) previous administration of any of the investigated antibiotics duringthe week before inclusion, (iv) chronic renal failure requiring dialysis and (v) allergy to any of the investigated drugs.",no,normal,"sepsis, septick shock",sepsis,septic shock,NA,NA,no,serum,no,"piperacillin, ceftazidime, cefepime, meropenem",penicillin,amikacin,HPLC,NONMEM 4,2,nonparametric bootstrap procedure,biological plausibility,NA,NA,yes
https://dx.doi.org/10.1016/j.ijantimicag.2017.12.015,36,Dhaese,2018,2018-01-01,Belgium,High-income,High-income,prospective PK study,110,Patients who were admitted to the surgical ICU and received continuous infusion of piperacillin,Patients who received extracorporeal membrane oxygenation or renal replacement therapy during piperacillin/tazobactam therapy and patients aged <18 years were excluded,no,normal,general ICU,general ICU,NA,NA,NA,no,plasma,no,piperacillin,penicillin,tazobactam,UHPLC-MS/MS,Pmetrics 1.5.0,1,"visual inspection, AIC, bias, imprecision",NA,NA,Monte Carlo,yes
https://dx.doi.org/10.1016/j.ijantimicag.2019.08.024,37,Dhaese,2019,2019-01-01,Belgium,High-income,High-income,prospective PK study,17,admitted to the surgical or medical ICU and received piperacillin/tazobactam (TZP) in continuous infusion,aged <18 years and those receiving extracorporeal membrane oxygenation or renal replacement therapy during antibiotic therapy were excluded from the study,no,normal,general ICU,general ICU,NA,NA,NA,no,plasma,no,piperacillin,penicillin,tazobactam,UPLC-MS/MS,Pmetrics 1.5.2,2,"goodness-of-fit plots, VPC, independent external validation dataset, LRT, AIC",biological plausibility,"stepwise forward inclusion, backward elimination",Monte Carlo,yes
https://dx.doi.org/10.1093/jac/dky434,38,Dhaese,2019,2019-01-01,Belgium,High-income,High-income,prospective PK study,68,admitted to the surgical ICU and received meropenem as a continuous infusion,Patients aged <18 years and patients receiving extracorporeal membrane oxygenation (ECMO) or renal replacement therapy (RRT) during meropenem drug therapy,no,normal,general ICU,general ICU,NA,NA,NA,no,plasma,no,meropenem,carbapenem,no,UPLC–MS/MS,Pmetrics 1.5.0,1,"VPC, goodness-of-fit plots, coefficient of determination of the linear regression, bias, imprecision, AIC, NPDE",NA,forward selection,NA,yes
https://dx.doi.org/10.2147/IDR.S373348,39,Dinh,2022,2022-01-01,Vietnam,Lower-middle-income,Middle-income,prospective PK study,24,admitted to the intensive care unit and got imipenem per clinical indication,"allergic to imipenem, <18 years old, pregnant or breastfeeding, or receiving dialysis",no,normal,general ICU,general ICU,NA,NA,NA,no,plasma,no,imipenem,carbapenem,no,HPLC-UV,Monolix 2019R1,2,"AIC, OFV, goodness-of-fit plots, NPDE, VPC",previously published covariates,COSSAC method,Monte Carlo,yes
https://dx.doi.org/10.1093/jac/dkac209,40,Dreesen,2022,2022-01-01,Belgium,High-income,High-income,prospective PK study,33,all adult patients admitted to the ICU with pneumonia and treated with ceftriaxone,Pregnant women and patients treated with renal replacement therapy,no,normal,pneumonia,pneumonia,NA,NA,NA,no,plasma,no,ceftriaxone,cephalosporin,no,HPLC-MS/MS,NONMEM 7.4,2,"OFV, VPC, goodness-of-fit plots, NPDE, bootstrapping",biological plausibility,likelihood ratio test,Monte Carlo,yes
https://dx.doi.org/10.1016/j.ijantimicag.2019.06.027,41,Economou,2019,2019-01-01,Australia,High-income,High-income,prospective PK study,6,(i) age ≥18 years; (ii) admission to an intensive care unit (ICU); (iii) clinical indication for TCC (only the combination formulation was available in Australia at the time of study); and (iv) receiving EDDf,(i) pregnant women; (ii) patients with active bleeding; or (iii) patients with human immunodeficiency virus (HIV) infection or hepatitis,RRT,impaired,EDDf,CRRT,NA,NA,NA,no,plasma,no,ticarcillin,penicillin,no,UHPLC-MS/MS,Pmetrics 1.5.1,2,"goodness-of-fit plots, coefficients of determination, log-likelihood values, bias, imprecision, bootstrapping, NPDE, VPC",biological plausibility,"stepwise linear regression, –2 log-likelihood value, goodness-of-fit plots",NA,yes
https://dx.doi.org/10.1016/j.ijantimicag.2019.06.016,42,Ehmann,2019,2019-01-01,Germany,High-income,High-income,prospective PK study,48,"presence of severe infection (confirmed or suspected by clinical assessment), age ≥ 18 years and therapy with meropenem",planned hospitalisation < 4 days or meropenem administration > 48 h prior to study start,"ECMO, RRT",impaired,sepsis,sepsis,NA,NA,NA,no,plasma,no,meropenem,carbapenem,no,UHPLC-MS/MS,NONMEM 7.3,2,"goodness-of-fit plots, VPC, bootstrapping, case-deletion diagnostics","biological plausibility, previously published covariates, graphical evaluation","stepwise forward inclusion, backward elimination",Monte Carlo,yes
https://dx.doi.org/10.1016/j.ijantimicag.2021.106289,43,Eisert,2021,2021-01-01,Germany,High-income,High-income,prospective PK study,32,"septic shock according to the SEPSIS-1 definition [18], being aged ≥ 18 years and necessity for treatment with meropenem, as determined by the treating physicians","pregnancy and post-organ transplantation status. A termination criterion was a change in antibiotic strategy during the study period, as indicated by treating physicians",RRT,impaired,septic shock,septic shock,NA,NA,NA,no,serum,no,meropenem,carbapenem,no,HPLC-UV,NONMEM 7.3,2,"OFV, goodness-of-fit plots, VPC, residual plots",NA,"stepwise forward inclusion, backward elimination",Monte Carlo,yes
https://dx.doi.org/10.1128/AAC.02090-12,44,Eyler,2014,2014-01-01,USA,High-income,High-income,prospective PK study,8,"≥18 years of age, receiving CVVHD/F, and prescribed ertapenem","pregnant and/or breastfeeding, had an allergy to ertapenem or another carbapenem, or had a severe, life-threatening reaction to penicillins or cephalosporins. Patients with a history of a central nervous system (CNS) disorder or who were currently experiencing a CNS infection were excluded as well. Finally, patients who were not expected to complete 24 h of CVVHD/F or who were concurrently receiving other extracorporeal therapies, such as extracorporeal membrane oxygenation, plasmapheresis, or intermittent hemodialysis, were also excluded",RRT,impaired,CRRT,CRRT,NA,NA,NA,no,serum,effluent,ertapenem,carbapenem,no,HPLC-MS/MS,NONMEM 7,2,"goodness-of-fit plots, OFV, VPC",NA,OFV,Monte Carlo,yes
https://dx.doi.org/10.1038/clpt.2014.131,45,Felton,2014,2014-01-01,UK,High-income,High-income,prospective PK study,18,Intubated patients who received piperacillin–tazobactam for suspected or documented pulmonary infection,NA,RRT,impaired,pneumonia,pneumonia,NA,NA,NA,no,plasma,epithelial lining fluid,piperacillin,penicillin,tazobactam,LC-MS/MS,Pmetrics 1.1.3,3,"log-likelihood value, coefficients of determination, slope and y-intercept from regression of the observed-predicted plots before and after the Bayesian step, AIC, VPC",NA,NA,Monte Carlo,no
https://dx.doi.org/10.1128/AAC.02664-14,46,Felton,2014,2014-01-01,UK,High-income,High-income,retrospective PK study,146,"Study 1: 76 patients undergoing abdominal or thoracic surgery who received 2 g of piperacillin over 30 min; Study 2: 12 hospitalized patients, who had received 3 g of piperacillin over 4 h every 8 h were included; Study 3: 40 ventilated patients with ventilator-associated pneumonia, administered piperacillin (12 g or 16 g) by continuous infusion",NA,no,unclear,general ICU,general ICU,NA,NA,NA,yes,plasma,no,piperacillin,penicillin,tazobactam,NA,Pmetrics 1.1.1,2,"VPC, log likelihood value, AIC, coefficients of determination",NA,NA,NA,yes
https://dx.doi.org/10.1093/jac/dkx541,47,Felton,2018,2018-01-01,UK,High-income,High-income,retrospective PK study,53,"Study 1: 13 critically ill, mechanically ventilated patients (4 patients were excluded from the analysis as they were receiving renal replacement therapy); Study 2: 40 critically ill patients with VAP",RRT,no,normal,"general ICU, VAP",VAP,NA,NA,NA,yes,serum,epithelial lining fluid,piperacillin,penicillin,tazobactam,"HPLC, LC–MS/MS",Pmetrics 1.4,3,"log-likelihood value, coefficients of determination, VPC, AIC",NA,NA,Monte Carlo,yes
https://dx.doi.org/10.1093/jac/dkab031,48,Fillatre,2021,2021-01-01,France,High-income,High-income,prospective PK study,42,(i) ECMO patients requiring antimicrobial therapy for sepsis;23 (ii) use of piperacillin/tazobactam; and (iii) the presence of an arterial line allowing iterative blood sampling for the PK study,"(i) pregnancy; (ii) restrictions due to rights deprivation, legal guardianship or trusteeship; and (iii) intermittent renal haemodialysis prior to inclusion","ECMO, RRT",impaired,ECMO,ECMO,NA,NA,NA,no,plasma,no,piperacillin,penicillin,tazobactam,HPLC-UV,Monolix 4.3.2,2,"-2 log likelihood, parameter accuracy, individual-weighted residuals, NPDE",NA,"reduction of the unexplained variability of the parameters, Wald test",NA,yes
https://dx.doi.org/10.1128/AAC.00505-18,49,Fournier,2018,2018-01-01,Switzerland,High-income,High-income,prospective PK study,21,all burn patients admitted to the Burn Centre who received a course of intravenous amoxicillin administered either alone or in combination with clavulanic acid,NA,no,unclear,burns,burns,NA,NA,NA,no,plasma,no,amoxicillin,penicillin,clavulanic acid,UPLC-MS/MS,NONMEM 7.1.0,2,"OFV, VPC, goodness-of-fit plots, bootstrapping",NA,"stepwise forward inclusion, backward elimination",Monte Carlo,yes
https://dx.doi.org/10.1093/jac/dkac261,50,Fratoni,2022,2022-01-01,USA,High-income,High-income,prospective PK study,9,"Patients with presumed ARC in the medical, surgical, and neurosurgical ICUs (as defined by Cockcroft-Gault calculated creatinine clearance ≥130 mL/min within 24 h of dosing) were considered eligible. Additional inclusion criteria were: (i) male or female aged 18–54 years old, (ii) APACHE II score ≥10 and ≤32, and (iii) a documented or presumed infection as defined by receipt of another antibiotic.","(i) currently pregnant or breast feeding, (ii) history of any hypersensitivity to a β-lactam antibiotic, (iii) history of chronic kidney disease or renal replacement therapy, (iv) suspected rhabdomyolysis or creatinine kinase >10 000 U/L, (v) any serum creatinine before dosing that was increased ≥0.3 mg/dL from the baseline used to qualify for enrolment, (vi) urinary output <20 mL/h for at least 2 h (oliguria) within 24 h before enrolment, (vii) sustained (at least 1 h) hypotension (systolic pressure <90 mmHg or mean arterial pressure <55 mmHg) refractory to vasopressor or fluid resuscitation for at least 24 h before enrolment, (viii) significant anaemia defined as a haemoglobin <8 g/dL at baseline, (ix) use of probenecid or imipenem/cilastatin within 3 days before study drug infusion, (x) current or anticipated use of valproic acid during study enrolment, (xi) acute liver injury, defined as AST or ALT >5 times the upper limes of normal (ULN), or AST or ALT >3×ULN with an associated total bilirubin >2×ULN, and (xii) planned or prior participation in any other interventional drug study within 30 days.",no,augmented,augmented renal clearance,augmented renal clearance,NA,NA,NA,no,plasma,no,imipenem,carbapenem,cilastatin/relebactam,LC-MS/MS,Pmetrics,2,"VPC, AIC, goodness-of-fit",NA,"stepwise forward inclusion, backward elimination",Monte Carlo,yes
https://dx.doi.org/10.1093/jac/dku354,51,Frippiat,2015,2015-01-01,Belgium,High-income,High-income,prospective PK study,55,age >18 years; diagnosis of late-onset (>5 days after admission) ventilator-associated pneumonia or hospital-acquired pneumonia requiring mechanical ventilation; and glomerular filtration rate (GFR) ≥30 mL/min (calculated according to the four-variable Modification of Diet in Renal Disease formula or by measurement of creatinine clearance based on 24 h urine) or acute kidney injury with indication for continuous venovenous haemofiltration (CVVH),pregnancy; life expectancy <3 days; allergy to β-lactams; GFR <30 mL/min and no required CVVH; previous use of meropenem within 15 days; and colonization with pathogens known to be resistant to meropenem,RRT,impaired,pneumonia,pneumonia,NA,NA,NA,no,plasma,epithelial lining fluid,meropenem,carbapenem,no,UPLC-UV,NONMEM 7.2,2,"VPC, bootstrapping, NPDE",NA,NA,Monte Carlo,yes
https://dx.doi.org/10.1111/j.1365-2125.2011.04005.x,52,Garot,2011,2011-01-01,France,High-income,High-income,prospective PK study,54,"at least 18 years of age, hospitalized in the ICU for sepsis, severe sepsis or septic shock, and treated with ceftriaxone","patients with haemopathies or allergies to cephalosporin, as well as patients under guardianship, undergoing chronic dialysis, not expected to live beyond 7 days, or having been treated with ceftriaxone for more than 24 hours",RRT,impaired,sepsis,sepsis,NA,NA,NA,no,plasma,no,ceftriaxone,cephalosporin,no,HPLC,NONMEM 6,2,"goodness-of-fit plots, AIC, VPC",biological plausibility,OFV,Monte Carlo,yes
https://dx.doi.org/10.1128/AAC.00430-09,53,Georges,2009,2009-01-01,France,High-income,High-income,prospective randomised PK trial,72,"(i) an inpatient stay in the ICU, (ii) over 18 years old, and (iii) presenting with P. aeruginosa nosocomial pneumonia or bacteremia with a strain thought to be sensitive to ceftazidime",NA,no,unclear,"pneumonia, sepsis",pneumonia,sepsis,NA,NA,no,plasma,no,ceftazidime,cephalosporin,no,HPLC-UV,NONMEM,2,OFV,biological plausibility,likelihood ratio test,NA,yes
https://dx.doi.org/10.2147/IDR.S343264,54,Gijsen,2022,2022-01-01,Belgium,High-income,High-income,prospective PK study,58,"All adult patients admitted to the ICU, treated with meropenem and having severe sepsis or septic shock (as defined according to the definitions applicable at the time of the study) at the start of meropenem therapy were screened for inclusion","pregnancy, do-not-resuscitate order, extracorporeal membrane oxygenation, renal replacement therapy, decreased renal function defined as an estimated glomerular filtration rate according to the Chronic Kidney Disease Epidemiology Collaboration equation (eGFRCKD-EPI) <70 mL/min/1.73 m2 on the day of PK sampling.",no,augmented,augmented renal clearance,augmented renal clearance,NA,NA,NA,no,plasma,no,meropenem,carbapenem,no,UHPLC-MS/MS,NONMEM 7.4,2,"VPC, bootstrapping","previously published covariates, expert consensus","stepwise forward inclusion, backward elimination",NA,yes
https://dx.doi.org/10.1186/2050-6511-15-21,55,Goncalves-Pereira,2014,2014-01-01,Portugal,High-income,High-income,prospective PK study,15,"Infected critically ill patients requiring intravenous meropenem (by decision of the attending physician), admitted to the intensive care unit (ICU) between May of 2009 and May of 2010, were recruited, irrespectively of comorbidities or of renal function",patients receiving renal replacement therapy,no,normal,sepsis,sepsis,NA,NA,NA,no,plasma,no,meropenem,carbapenem,no,HPLC-UV,WinNonlin 5.0.1,2,NA,biological plausibility,NA,NA,yes
https://dx.doi.org/10.1186/s13613-020-00666-8,56,Grensemann,2020,2020-01-01,Germany,High-income,High-income,prospective PK study,19,receiving meropenem for clinical indication and required CVVHD,< 18 years or with an extracorporeal circuit other than the CVVHD,RRT,impaired,liver failure,liver failure,NA,NA,NA,no,serum,no,meropenem,carbapenem,no,HPLC-DAD,NONMEM 7.4,2,"VPC, scatter plots, likelihood-ratio test",NA,NA,Monte Carlo,no
https://dx.doi.org/10.1128/Spectrum.00633-21,57,Hahn,2021,2021-01-01,South Korea,High-income,High-income,prospective PK study,26,critically ill patients aged 19 years or older who were admitted to the CCU for venoarterial (VA) ECMO and were prescribed piperacillin-tazobactam,use of drugs known to change the plasma concentrations of piperacillin-tazobactam,"ECMO, RRT",impaired,ECMO,ECMO,NA,NA,NA,no,plasma,no,piperacillin,penicillin,tazobactam,LC-MS/MS,NONMEM 7.4,2,"OFV, goodness-of-fit plots, relative standard errors, VPC",biological plausibility,"scatter plots, stepwise forward inclusion, backward elimination",Monte Carlo,yes
https://dx.doi.org/10.1128/AAC.02390-17,58,Hanberg,2018,2018-01-01,Denmark,High-income,High-income,prospective PK study,10,Patients on ECMO treatment who were treated with meropenem,Patients under the age of 18 and patients who were pregnant,"ECMO, RRT",impaired,ECMO,ECMO,NA,NA,NA,no,plasma,subcutaneous tissue,meropenem,carbapenem,no,UHPLC-UV,NONMEM 7.3,2,"OFV, VPC, goodness-of-fit plots",NA,"stepwise forward inclusion, backward elimination",Monte Carlo,yes
https://dx.doi.org/10.1128/aac.02189-21,60,Heffernan,2022,2022-01-01,Australia,High-income,High-income,retrospective PK study,36,"Study 1: Twelve adult patients in the ICU with severe sepsis and who received ceftriaxone; Study 2: 17 patients, not clear what inclusion criteria; Study 3: adult patients (age ≥18 years) admitted to the ICU receiving ceftriaxone intravenously for the treatment of sepsis with an extraventricular drain were eligible",Study 1: Patients with suspected allergy or renal impairment (plasma creatinine >120 μmol/L at enrolment) were excluded; Study 2: not clear; Study 3: Patients who were pregnant or receiving either intermittent or continuous hemodialysis,no,normal,"sepsis, EVD",sepsis,EVD,NA,NA,no,plasma,no,ceftriaxone,cephalosporin,no,UHPLC-MS/MS,Pmetrics 1.5.2,2,"VPC, AIC, BIC, log-likelihood ratios, goodness-of-fit plots",biological plausibility,"log-likelihood ratios, AIC, BIC, goodness-of-fit plots",Monte Carlo,yes
https://dx.doi.org/10.1007/s00228-019-02716-y,61,Idoate Grijalba,2019,2019-01-01,France,High-income,High-income,retrospective PK study,80,"aged over 18 years, admitted to ICU, treated with empirical or targeted therapy with meropenem, and had received at least 3 doses of meropenem prior to monitoring",All critically ill patients who had received renal replacement therapy,no,normal,general ICU,general ICU,NA,NA,NA,no,serum,no,meropenem,carbapenem,no,HPLC,Pmetrics,1,"VPC, AIC, BIC",NA,"AIC, BIC, scatter plots, RMSE, VPC",Monte Carlo,yes
https://dx.doi.org/10.2165/00003088-200847030-00003,63,Isla,2008,2008-01-01,Spain,High-income,High-income,prospective PK study,20,(i) age >18 years; (ii) treatment with CRRT for >1 day for ≥20 h/day; and (iii) isolated or expected causative pathogen susceptible to meropenem,NA,RRT,impaired,"CRRT, sepsis, trauma",CRRT,sepsis,trauma,NA,no,plasma,dialysate-ultrafiltrate fluid,meropenem,carbapenem,no,HPLC,NONMEM 5,2,"VPC, bootstrapping, goodness-of-fit",NA,"-2 log likelihood, stepwise forward inclusion, backward elimination",NA,yes
https://dx.doi.org/10.1128/AAC.02534-17,64,Jacobs,2018,2018-01-01,Belgium,High-income,High-income,retrospective PK study,215,"(i) diagnosis of sepsis or septic shock according to standard criteria (35), (ii) therapy with a standard dosage regimen of a broad-spectrum β-lactam (FEP/CAZ, 2 g every 8 h [q8h]; TZP, 4.5 g q6h; or MEM, 1 g q8h), and (iii) mCLCR of≥120 ml/min (so that all patients close to the threshold of ARC could be included in the study) on the day of TDM","Incomplete TDMs (missing measured drug concentrations at T0 or T2) were excluded, as were TDMs performed on patients with burns or cystic fibrosis and those who were treated with extracorporeal membrane oxygenation. Patients could be included more than once.",no,augmented,augmented renal clearance,augmented renal clearance,NA,NA,NA,no,serum,no,"meropenem, cefepime, ceftazidime, piperacillin",penicillin,no,HPLC-UV,Pmetrics,1,"linear regression, coefficients of determination, VPC, -2 log likelihood, bias, imprecision, bootstrapping, NPDE",biological plausibility,"stepwise forward inclusion, backward elimination",NA,yes
https://dx.doi.org/10.1093/jac/dkaa187,65,Jager,2020,2020-01-01,Australia,High-income,High-income,retrospective PK study,35,"Study 1: age between 18 and 80 years old, known or suspected infection produced by MSSA, hypoalbuminaemia arbitrarily defined as albumin plasma levels ≤32 g/L and without severe renal dysfunction arbitrarily defined as plasma creatinine concentration <170 µmol/L; Study 2: ≥18 years old, receiving one of the selected study antibiotic(s), would have received at least four doses of antibiotic by the time of sampling and were expected to remain on the treatment for the next 24 h",Study 1: NR; Study 2: NR,no,normal,"hypoalbuminaemia, general ICU",hypoalbuminaemia,NA,NA,NA,no,plasma,no,flucloxacillin,penicillin,no,HPLC-UV,NONMEM 7.1.2,2,"bootstrapping, OFV, VPC",biological plausibility,"stepwise forward inclusion, backward elimination, OFV",Monte Carlo,yes
https://dx.doi.org/10.1128/AAC.04166-14,66,Jaruratanasirikul,2015,2015-01-01,Thailand,Upper-middle-income,Middle-income,prospective PK study,9,"(i) >18 years of age and (ii) with a diagnosis of severe sepsis or septic shock, either at admission or during the ICU stay","pregnant, had documented hypersensitivity to carbapenems, or had a history of chronic kidney disease",no,normal,"sepsis, septic shock",sepsis,septic shock,NA,NA,no,plasma,no,meropenem,carbapenem,no,HPLC,NONMEM 7.2,1,"OFV, goodness-of-fit plots, VPC, AIC",NA,"stepwise forward inclusion, backward elimination, OFV",Monte Carlo,yes
https://dx.doi.org/10.1007/s40261-019-00796-3,67,Jaruratanasirikul,2019,2019-01-01,Thailand,Upper-middle-income,Middle-income,prospective PK study,10,"aged ≥ 18 years with cardiopulmonary failure and were supported by ECMO receiving a 1-h infusion of 0.5 g imipenem/cilastatin diluted in 100 mL of normal saline solution, delivered via infusion pump at a constant flow rate, every 6 h for the treatment of severe infections for 14 days",NA,ECMO,unclear,ECMO,ECMO,NA,NA,NA,yes,plasma,no,imipenem,carbapenem,no,HPLC,WinNonlin 1.1,2,NA,NA,NA,NA,yes
https://dx.doi.org/10.1128/AAC.02089-13,70,Jeon,2014,2014-01-01,South Korea,High-income,High-income,prospective PK study,50,burns ranging from 1% to 81% of their total body surface area (TBSA) who were treated with piperacillin-tazobactam,"pregnant, breastfeeding, <18 years old, or allergic to penicillin",no,unclear,burns,burns,NA,NA,NA,no,plasma,no,piperacillin,penicillin,tazobactam,LC-MS/MS,NONMEM 7.2,2,"OFV, bootstrapping, VPC",NA,"stepwise forward inclusion, backward elimination",Monte Carlo,yes
http://dx.doi.org/10.1093/jac/dkw171,71,Jonckheere,2016,2016-01-01,Belgium,High-income,High-income,prospective PK study,20,patients during the first 3 days of cefepime therapy,NA,RRT,impaired,general ICU,general ICU,NA,NA,NA,yes,plasma,urine,cefepime,cephalosporin,no,LC-MS/MS,NONMEM 7.3,2,"OFV, goodness-of-fit plots",NA,"stepwise forward inclusion, backward elimination, OFV, goodness-of-fit",Monte Carlo,yes
https://dx.doi.org/10.3390/jcm11226621,73,Kang,2022,2022-01-01,South Korea,High-income,High-income,prospective PK study,13,adult patients (≥18 years) receiving V-A ECMO and concomitantly receiving meropenem,patients who were allergic to carbapenem or pregnant were excluded,"ECMO, RRT",impaired,ECMO,ECMO,NA,NA,NA,no,plasma,no,meropenem,carbapenem,no,LC-MS,"NONMEM 7.4.1, Pirana 2.9.7",2,"VPC, SIR, OFV",biological plausibility,"stepwise forward inclusion, backward elimination, OFV, goodness-of-fit",Monte Carlo,yes
https://dx.doi.org/10.1177/1060028018773771,74,Kanji,2018,2018-01-01,Canada,High-income,High-income,prospective PK study,34,"18 years of age or older, admitted to 1 of the 2 participating ICUs, and receiving SLED and any dose of piperacillin/tazobactam","hypermetabolic state resulting from >25% coverage of body surface area burn, cystic fibrosis or spinal cord injury, bariatric patients (defined as >150 kg total body weight at the time of recruitment), pregnancy, absence of a closed system arterial or central venous catheter (to minimize blood wastage), and concomitant therapy with probenecid",RRT,impaired,CRRT,CRRT,NA,NA,NA,no,plasma,no,piperacillin,penicillin,tazobactam,LC-MS/MS,Pmetrics,2,"log-likelihood ratios, NPDE, VPC",NA,"stepwise linear regression, -2LL, goodness-of-fit",Monte Carlo,yes
https://dx.doi.org/10.1002/jcph.600,76,Kees,2016,2016-01-01,Germany,High-income,High-income,prospective PK study,32,Adult patients (≥18 years) who received continuous infusion of meropenem and were not on renal replacement therapy were eligible for study participation,Not on renal replacement therapy,no,normal,general ICU,general ICU,NA,NA,NA,no,plasma,no,meropenem,carbapenem,no,HPLC,NONMEM 7.3,NA,"goodness-of-fit, bootstrapping, case deletion diagnostics",biological plausibility,"stepwise forward inclusion, backward elimination, OFV",NA,yes
https://dx.doi.org/10.1093/jac/dkac059,77,Kim,2022,2022-01-01,South Korea,High-income,High-income,prospective PK study,38,"nosocomial infections, empirical management of septic shock from an unknown source, and prophylactic administration for patients undergoing ECMO",a history of penicillin allergy or a positive skin test result for piperacillin,"ECMO, RRT",impaired,"ECMO, CRRT",ECMO,CRRT,NA,NA,no,plasma,no,piperacillin,penicillin,tazobactam,LC-MS/MS,NONMEM 7.5,2,"OFV, precision, shrinkage of IIV, goodness-of-fit plots",biological plausibility,"stepwise forward inclusion, backward elimination, VPC, bootstrapping",Monte Carlo,yes
https://dx.doi.org/10.1128/AAC.02556-19,79,Klastrup,2020,2020-01-01,Denmark,High-income,High-income,prospective PK study,78,"Critically ill patients treated empirically or targeted with piperacillin-tazobactam, administered as continuous infusion",treated with renal replacement therapy or extracorporeal membrane oxygenation or were under the age of 18 years,no,normal,general ICU,general ICU,NA,NA,NA,no,plasma,no,piperacillin,penicillin,tazobactam,UHPLC,NONMEM 7.4.3,1,"likelihood ratio test, OFV, VPC, goodness-of-fit",NA,"stepwise forward inclusion, backward elimination",Monte Carlo,yes
https://dx.doi.org/10.1016/j.ijantimicag.2022.106603,80,Kois,2022,2022-01-01,USA,High-income,High-income,prospective PK study,6,"≥18 years old, receiving veno-arterial (VA) or veno-venous (VV) ECMO, and receiving cefepime as part of their standard-of-care antibiotic regimen",NA,"ECMO, RRT",impaired,ECMO,ECMO,NA,NA,NA,no,plasma,no,cefepime,cephalosporin,no,LC-MS/MS,Pmetrics,2,"AIC, VPC",NA,NA,Monte Carlo,no
https://dx.doi.org/10.1093/jac/dkw592,81,Konig,2017,2017-01-01,Germany,High-income,High-income,prospective PK study,16,The inclusion criteria were age ≥18 years and antibiotic treatment with ceftazidime in septic patients receiving sustained low efficiency dialysis (SLED),Patients receiving SLED at night were excluded for logistics reasons.,RRT,impaired,CRRT,CRRT,NA,NA,NA,no,serum,no,ceftazidime,cephalosporin,no,HPLC-UV,Pmetrics,2,"goodness-of-fit, bias, imprecision",biological plausibility,stepwise,Monte Carlo,yes
https://dx.doi.org/10.1186/s13613-019-0622-8,82,Kothekar,2020,2020-01-01,India,Lower-middle-income,Middle-income,prospective PK study,25,"We included patients aged 18–70 years of either sex, with known or suspected severe sepsis or septic shock admitted to the ICU and receiving meropenem 1000 mg 3-h extended infusion (EL) eight hourly (Q8H) as a standard of care. Severe sepsis and septic shock were diagnosed according to the American–European Consensus Conference (AECC) criteria.","Patients who had received any carbapenem in the previous 72 h, those with baseline predicted creatinine clearance less than 50 mL/min [20] and those not expected to survive more than 72 h were excluded from the study",no,normal,"severe sepsis, septic shock",sepsis,septic shock,NA,NA,no,plasma,no,meropenem,carbapenem,no,HPLC,WinNonlin,1,least squares,NA,NA,NA,no
https://dx.doi.org/10.1128/aac.42.9.2421,83,Krueger,1998,1998-01-01,Germany,High-income,High-income,prospective PK study,9,NA,NA,RRT,impaired,anuric CRRT,anuric CRRT,NA,NA,NA,no,plasma,diafiltrate,meropenem,carbapenem,no,HPLC-UV,MODFIT,2,least square regression,NA,NA,NA,no
https://dx.doi.org/10.1128/aac.00142-22,84,Kumta,2022,2022-01-01,International,High-income,High-income,prospective PK study,8,(i) age 18 to 85 years; (ii) EVD in situ; (iii) receiving meropenem treatment; and (iv) a diagnosis of ventriculitis or extracranial infection,"(i) small ventricles as determined by computed tomography with intracranial pressure of >20 mmHg; (ii) preexisting renal impairment, defined as the need for replacement therapy or a serum creatinine concentration of >200 µmol/L on the day of participant screening; (iii) preexisting hepatic dysfunction, defined as a gamma glutamyl transferase level of >200 IU/L; (iv) hypersensitivity to beta-lactams; (v) pregnancy; and (vi) patients in whom death was deemed inevitable within 24 h",no,normal,ventriculitis or extracranial infection,CNS infection,NA,NA,NA,no,plasma,CSF,meropenem,carbapenem,no,UHPLC-MS/MS,Pmetrics 1.5.2,3,"AIC, BIC, LLR, goodness-of-fit",NA,NA,Monte Carlo,yes
https://dx.doi.org/10.1128/AAC.02052-21,85,Layios,2022,2022-01-01,Belgium,High-income,High-income,prospective PK study,32,age > 18; diagnosis of ventilator-associated pneumonia (VAP) or hospital-acquired pneumonia (HAP) requiring mechanical ventilation with a documented pathogen showing temocillin Vitek 2 in vitro sensitivity of ≤8 mg/L; and creatinine clearance based on 24-h urine output collection and measurement ≥30 mL/min/1.73 m2,NA,no,normal,"VAP, HAP",VAP,HAP,NA,NA,no,blood,epithelial lining fluid,temocillin,penicillin,no,UHPLC-MS/MS,NONMEM 7.4.0,2,"goodness-of-fit, VPC",NA,OFV,Monte Carlo,yes
https://dx.doi.org/10.3389/fphar.2021.768912,86,Lee,2021,2021-01-01,South Korea,High-income,High-income,prospective PK study,30,patients (aged ≥19) who underwent ECMO for respiratory and/or cardiac dysfunction and who received meropenem for treatment or prophylaxis,NA,"ECMO, RRT",impaired,ECMO,ECMO,NA,NA,NA,no,plasma,no,meropenem,carbapenem,no,HPLC-MS/MS,NONMEM 7.5,2,"OFV, RSE, goodness-of-fit, LLR",clinical relevance,"stepwise forward inclusion, backward elimination, VPC, bootstrapping",Monte Carlo,yes
https://dx.doi.org/10.3390/pharmaceutics13111861,87,Lee,2021,2021-01-01,South Korea,High-income,High-income,prospective PK study,26,"empirical management of sepsis from unknown source, nosocomial infections, and prophylactic administration for patients undergoing ECMO",Patients with a history of β-lactam allergy or a positive skin test result for meropenem,"ECMO, RRT",impaired,"ECMO, non-ECMO",ECMO,non-ECMO,NA,NA,no,plasma,no,meropenem,carbapenem,no,HPLC-MS/MS,NONMEM 7.5,2,"OFV, RSE, goodness-of-fit, LLR",clinical relevance,"stepwise forward inclusion, backward elimination, VPC, bootstrapping",Monte Carlo,yes
https://dx.doi.org/10.1093/jac/dkaa067,88,Leegwater,2020,2020-01-01,Netherlands,High-income,High-income,prospective PK study,55,Patients aged ≥18 years were eligible for inclusion if ceftriaxone therapy was initiated in the ICU,"allergies to cephalosporins, <12 h life expectancy and the requirement for any form of renal replacement therapy",no,normal,general ICU,general ICU,NA,NA,NA,no,blood,no,ceftriaxone,cephalosporin,no,LC-MS/MS,"NONMEM 7.4.1, Pirana 2.9.8",1,"shrinkage, OFV, goodness-of-fit, IIV, precision, bootstrapping, VPC","biological plausibility, previously published",OFV,Monte Carlo,yes
https://dx.doi.org/10.1016/j.ijantimicag.2018.10.006,90,Li,2019,2019-01-01,Belgium,High-income,High-income,retrospective PK study,20,Study 1: 1) adult; 2) admission to ICU; 3) treatment with imipenem and CRRT simultaneously; Study 2: All patients 18 years or older in the Firefighters’ Burn Center Intensive Care Unit at Regional One Health receiving I/C for any infectious indication and requiring high-dose CVVH were eligible for inclusion,Study 1: Patients who were judged inappropriate to get frequent blood samples by the attending physician; Study 2: NR,RRT,impaired,"CRRT, burns",burns,CRRT,NA,NA,no,plasma,no,imipenem,carbapenem,no,"HILIC-MS, HPLC-UV","NONMEM 7.3, PSN 4.60, Pirana 2.9.6",1,"OFV, condition number, relative standard error, goodness-of-fit, VPC, NPDE, SIR",NA,"stepwise forward inclusion, graphical exploration, empirical Bayes estimates",Monte Carlo,yes
https://dx.doi.org/10.1016/j.clinthera.2020.06.010,91,Li,2020,2020-01-01,China,Upper-middle-income,Middle-income,prospective PK study,30,"adult, admission to the intensive care unit, and simultaneous treatment with imipenem and CRRT",NA,RRT,impaired,CRRT,CRRT,NA,NA,NA,no,plasma,effluent,imipenem,carbapenem,no,HPLC-UV,Phoenix 8.0,3,"bootstrapping, VPC",NA,"stepwise forward inclusion, backward elimination, goodness-of-fit, OFV",Monte Carlo,yes
https://dx.doi.org/10.3390/antibiotics10040468,92,Liebchen,2021,2021-01-01,Germany,High-income,High-income,retrospective PK study,155,Patients with characteristics within the 90% range of the characteristics of the original dataset used for the PK model development were selected for the evaluation.,Patients undergoing renal replacement therapy and patients with creatinine clearances outside the range of applicability of the MeroRisk-Calculator (25–255 mL/min) were excluded,no,normal,general ICU,general ICU,NA,NA,NA,no,serum,no,meropenem,carbapenem,no,LC-MS/MS,NA,2,simulations,NA,"piecewise linear, power and linear relationship",NA,yes
https://dx.doi.org/10.1128/aac.43.10.2559,93,Lipman,1999,1999-01-01,Australia,High-income,High-income,prospective PK study,10,"Critically ill patients ranging in age from 18 to 75 years for whom the staff intensive care specialist deemed cefepime to be appropriate therapy were enrollable if they had an infected site as defined by clinical suspicion with or without positive culture results, systemic inflammatory response syndrome, and serum creatinine level of <0.1 mmol/liter","renal dysfunction (creatinine clearance, <75 ml/min)",no,normal,sepsis,sepsis,NA,NA,NA,no,plasma,no,cefepime,cephalosporin,no,HPLC,WinNonlin,2,NA,NA,NA,NA,no
https://dx.doi.org/10.1007/s001340000741,94,Lipman,2001,2001-01-01,Australia,High-income,High-income,prospective PK study,12,(a) 18-75 years of age; (b) infected site as defined by clinical suspicion with or without positive culture results; (c) systemic inflammatory response syndrome; (d) informed consent given by patient or next of kin; (e) normal renal function; (f) an intra-arterial cannula in situ,NA,no,normal,sepsis,sepsis,NA,NA,NA,no,plasma,no,cefpirome,cephalosporin,no,HPLC,WinNonlin,2,simulations,NA,NA,NA,no
https://dx.doi.org/10.1097/FTD.0000000000000323,95,Mathew,2016,2016-01-01,India,Lower-middle-income,Middle-income,prospective PK study,35,"Adult patients admitted to the ICU and initiated on meropenem at a dose of 1000 mg (twice or thrice daily) were recruited into the study after obtaining a written informed consent from the patient or the closest relative of the patient. Meropenem was initiated for the treatment of sepsis, pneumonia, polytrauma, complicated urinary tract infection, or as empirical therapy",Patients who were on dialysis,no,normal,"sepsis, trauma",sepsis,trauma,NA,NA,no,plasma,no,meropenem,carbapenem,no,HPLC,Pmetrics 1.4.1,2,"coefficient of determination, LLR, AIC, median absolute weighted deviation, MCS",NA,"stepwise forward inclusion, backward elimination",Monte Carlo,yes
https://dx.doi.org/10.1007/s00228-016-2053-x,96,Mattioli,2016,2016-01-01,Italy,High-income,High-income,prospective PK study,27,"patients admitted to ICUs who developed a Klebsiella pneumoniae (KP) nosocomial infection treated with meropenem alone or in combination depending on the resistance profile of the bacterial strain, meropenem administration for at least 2 days, and bacteremia confirmed by at least one positive blood culture",Patients undergoing dialysis procedures,no,normal,Klebsiella sepsis,sepsis,NA,NA,NA,no,plasma,no,meropenem,carbapenem,no,HPLC,NONMEM 7.2,1,"OFV, goodness-of-fit, VPC, bootstrapping",NA,generalized additive modeling,NA,yes
https://dx.doi.org/10.1093/jac/dkx526,97,Minichmayr,2018,2018-01-01,Germany,High-income,High-income,retrospective PK study,195,"Adult critically ill patients, who received continuous infusion of meropenem",renal replacement therapy,no,normal,general ICU,general ICU,NA,NA,NA,no,plasma,no,meropenem,carbapenem,no,HPLC-UV,NONMEM 7.3,NA,"OFV, goodness-of-fit, VPC, bootstrapping, NPDE",NA,"OFV, LLR",Monte Carlo,yes
https://dx.doi.org/10.1128/AAC.46.5.1557-1560.2002,98,Mueller,2002,2002-01-01,Germany,High-income,High-income,prospective PK study,8,"age of >18 years, acute renal failure treated by CVVHD, anuria (<100 ml of urine/day), and treatment with piperacillin-tazobactam",Patients with severe liver failure or cholestasis were excluded,RRT,impaired,CRRT,CRRT,NA,NA,NA,no,plasma,dialysate,piperacillin,penicillin,tazobactam,HPLC-UV,Topfit 2.0,1,AIC,NA,NA,simulations,no
https://dx.doi.org/10.1136/ejhpharm-2022-003535,99,Murinova,2022,2022-01-01,Czech Republic,High-income,High-income,retrospective PK study,144,"age ≥18 years, not receiving dialysis, receiving intravenous meropenem to treat a serious bacterial infection defined as the development of potentially life-threatening clinical manifestations, and having at least one measured meropenem serum level in the course of meropenem therapy",NA,no,normal,sepsis,sepsis,NA,NA,NA,no,serum,no,meropenem,carbapenem,no,LC-MS/MS,Monolix 2021R1,1,"goodness-of-fit, NPDE, VPC",NA,"stepwise forward inclusion, backward elimination, OFV, goodness-of-fit",Monte Carlo,yes
https://dx.doi.org/10.1128/AAC.01649-09,100,Nandy,2010,2010-01-01,USA,High-income,High-income,retrospective PK study,285,"In the phase 2 study of patients with complicated UTI or pyelonephritis, doripenem at 250 to 500 mg was infused over 60 min every 8 h. In the two phase 3 studies of patients with nosocomial pneumonia, doripenem at 500 mg was infused over either 1 or 4 h every 8 h.",NA,no,unclear,"sepsis, UTI, pyelonephritis, pneumonia",sepsis,UTI,pyelonephritis,pneumonia,yes,plasma,no,doripenem,carbapenem,no,LC-MS/MS,NONMEM V,2,"goodness-of-fit, OFV, AIC, residual error variance",NA,"stepwise forward inclusion, backward elimination, generalized additive modeling, OFV",NA,yes
https://dx.doi.org/10.1128/AAC.01141-08,101,Nicasio,2009,2009-01-01,USA,High-income,High-income,prospective PK study,26,"adult patients (≥18 years old) in the ICU, who were placed on the VAP clinical pathway and prescribed cefepime",severely impaired renal function requiring dialysis and those deemed poor candidates for blood collection,no,normal,VAP,VAP,NA,NA,NA,no,serum,no,cefepime,cephalosporin,"vancomycin, tobramycin (or a fluoroquinolone if tobramycin was contraindicated)",HPLC,MM-USC*PACK,2,"LLR, AIC, coefficients of determination, VPC, bias, precision",NA,NA,Monte Carlo,yes
https://dx.doi.org/10.1097/FTD.0000000000000741,102,Niibe,2020,2020-01-01,Japan,High-income,High-income,prospective PK study,21,"admitted to the ICU between July 2016 to March 2018, inclusive, and who were treated with an intravenous infusion of meropenem and were receiving CHDF",Patients younger than 20 years and those who declined to participate in the study,RRT,impaired,CRRT,CRRT,NA,NA,NA,no,serum,no,meropenem,carbapenem,no,HPLC,Phoenix 7.0,2,"OFV, AIC, goodness-of-fit, VPC, bootstrapping",NA,"stepwise forward inclusion, backward elimination",Monte Carlo,yes
https://dx.doi.org/10.1016/j.jiac.2021.12.017,103,Niibe,2022,2022-01-01,Japan,High-income,High-income,prospective PK study,12,"age ≥18 years, both medical and surgical origin of ICU admission between July 2016 to September 2017, and treatment with an intravenous infusion of meropenem initiated after ICU admission",received renal replacement therapy or if they declined to participate in the study,no,normal,general ICU,general ICU,NA,NA,NA,no,serum,no,meropenem,carbapenem,no,HPLC,Phoenix 7.0,2,"OFV, AIC, goodness-of-fit, VPC, bootstrapping",NA,"stepwise forward inclusion, backward elimination, OFV",Monte Carlo,yes
https://dx.doi.org/10.1038/s41598-020-79076-6,104,Nonoshita,2020,2020-01-01,Japan,High-income,High-income,prospective PK study,21,"in ICU treated with DRPM, who gave written informed consent obtained from either the patients or their legally authorized representatives",Patients who were administered other carbapenem antibacterial agents before administration of DRPM were excluded,RRT,impaired,general ICU,general ICU,NA,NA,NA,no,plasma,no,doripenem,carbapenem,no,HPLC,NONMEM 7.3.0,2,"OFV, AIC, goodness-of-fit, bootstrapping",clinical plausibility,"stepwise forward inclusion, backward elimination, OFV",Monte Carlo,yes
https://dx.doi.org/10.1007/s13318-021-00709-w,105,O'Jeanson,2021,2021-01-01,France,High-income,High-income,retrospective PK study,58,known or suspected infection of a critically ill patient in the medical ICU and treated with meropenem,age (< 18 years old),RRT,impaired,general ICU,general ICU,NA,NA,NA,no,serum,no,meropenem,carbapenem,no,UHPLC-UV,NONMEM 7.4.1,1,"OFV, AIC, goodness-of-fit, VPC, NPDE, precision, bias",biological plausibility,"stepwise forward inclusion, backward elimination, OFV",Monte Carlo,yes
https://dx.doi.org/10.1128/AAC.02134-18,106,Ollivier,2019,2019-01-01,France,High-income,High-income,prospective PK study,21,"(i) the patient was ≥18 years of age, (ii) the patient had a first episode of sepsis (defined as presumed or confirmed infection with new organ dysfunction in the previous 48 h), (iii) the patient had been treated with ceftriaxone for less than 24 h at the time of the assessment, and (iv) the patient had an expected ICU stay of greater than 72 h",renal impairment (CLCR < 60 ml/min) and/or receipt of renal replacement therapy,no,normal,sepsis,sepsis,NA,NA,NA,no,plasma,no,ceftriaxone,cephalosporin,no,HPLC-UV,Monolix,2,"LLR, OFV, VPC, NPDE, PWRES, IWRES, bootstrapping, AIC, BIC, goodness-of-fit, RSE",NA,"stepwise forward inclusion, BIC, backward selection, LRT",Monte Carlo,yes
https://dx.doi.org/10.1007/s43440-020-00104-3,107,Onichimowski,2020,2020-01-01,Poland,High-income,High-income,prospective PK study,19,"age 18–80 years, both medical and surgical origin of ICU admission, treatment with licensed doses of meropenem (1 g every 8 h), and clinical indications for CRRT due to AKI, determined in accordance with the criteria adopted by Kidney Disease Improving Global Outcomes (KDIGO) recommendations","diagnosed with HIV infection or terminal cancer, displayed intolerance or allergy to beta-lactam antibiotics in the past, had a high probability of bacterial infection with meropenem resistant strains, and received meropenem up to 3 months before being screened",RRT,impaired,CRRT,CRRT,NA,NA,NA,no,plasma,no,meropenem,carbapenem,no,HPLC,NONMEM 7.4.1,2,"VPC, bootstrapping",biological plausibility,"OFV, stepwise forward inclusion, backward elimination",Monte Carlo,yes
https://dx.doi.org/10.1093/jac/dkz299,108,Padulles Zamora,2019,2019-01-01,Spain,High-income,High-income,prospective PK study,12,"(i) sepsis with acute renal failure requiring CRRT with high-adsorbent membranes for >48 h; (ii) age ≥18 years; and (iii) isolated or expected causative pathogen susceptible to meropenem, prescribed at the discretion of the treating physician",(i) hypersensitivity to meropenem or penicillin; (ii) neoplasia with metastasis and a life expectancy of <6 months; and (iii) pregnant or breastfeeding women,RRT,impaired,CRRT,CRRT,NA,NA,NA,no,plasma,ultrafiltrate,meropenem,carbapenem,no,UHPLC-MS/MS,NONMEM 7.3,2,"OFV, AIC, bootstrapping, VPC, goodness-of-fit, precision",NA,"univariate analysis, stepwise forward inclusion, backward elimination",Monte Carlo,yes
https://dx.doi.org/10.3390/antibiotics11070898,109,Pokem,2022,2022-01-01,Belgium,High-income,High-income,prospective PK study,19,"patients with septic shock, >18 years old, diagnosed with an IAI caused by a pathogen expected to be susceptible to temocillin","patients allergic to any penicillin, including temocillin, pregnant or lactating women; or patients having participated in another experimental study with the same drug during the 4 preceding weeks",no,unclear,"septic shock, abdominal sepsis",septic shock,abdominal sepsis,NA,NA,no,plasma,ascites,temocillin,penicillin,yes,HPLC-MS/MS,Pmetrics 1.5.1,2,"AIC, VPC, 2LL, goodness-of-fit, bias, imprecision, shrinkage",biological plausibility,"univariate associations, Bayesian estimates, forward inclusion, backward elimination, 2LL, goodness-of-fit",Monte Carlo,yes
https://dx.doi.org/10.1002/jcph.1865,110,Por,2021,2021-01-01,USA,High-income,High-income,prospective PK study,23,NA,NA,RRT,impaired,"burns, CRRT",burns,CRRT,NA,NA,no,plasma,"postfilter plasma, ultrafiltrate",imipenem,carbapenem,no,HPLC-UV,Pumas 1.05,2,"LRT, diagnostic plots, plausibility, precision, goodness-of-fit, bootstrapping, VPC, NPDE",previously published,stepwise inclusion,Monte Carlo,yes
https://dx.doi.org/10.1089/sur.2015.113,111,Rahbar,2016,2016-01-01,USA,High-income,High-income,prospective PK study,27,"age ≥18 years, admission to the Emory surgical intensive care unit (SICU) service for greater than 24 hours, and a diagnosis of sepsis that necessitated empiric antimicrobial therapy","acute or chronic renal dysfunction (urine output less than 0.5 mL/kg/h or calculated creatinine clearance (CLcr) of less than 50 mL/min by Cockroft-Gault equation), pregnancy, known allergy to beta-lactam antibiotics, non-English–speaking, or if they were enrolled in another clinical trial",no,normal,"trauma, sepsis",trauma,sepsis,NA,NA,no,serum,no,doripenem,carbapenem,no,HPLC,BigNPAG,2,"bias, precision, LLR, coefficients of determination, goodness-of-fit, Bayesian analysis",NA,NA,Monte Carlo,no
https://dx.doi.org/10.1177/0091270003260286,113,Robatel,2003,2003-01-01,Switzerland,High-income,High-income,prospective PK study,15,treated by CVVHDF and receiving meropenem since at least 1 day,"filter clotting, sample timings/storage",RRT,impaired,CRRT,CRRT,NA,NA,NA,no,plasma,filtrate-dialysate,meropenem,carbapenem,yes,HPLC-UV,Kinetica,4,AIC,NA,NA,NA,no
https://dx.doi.org/10.1097/CCM.0b013e3181968e44,114,Roberts,2009,2009-01-01,Australia,High-income,High-income,prospective randomised PK trial,13,Critically ill adult patients with known or suspected sepsis in whom the treating physician deemed piperacillin–tazobactam appropriate therapy were conveniently sampled. Sepsis was diagnosed according to the criteria of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Committee,"Patients with a known or suspected allergy to penicillin, piperacillin–tazobactam, or renal impairment (defined as plasma creatinine >120 μM/L)",no,normal,sepsis,sepsis,NA,NA,NA,no,plasma,subcutaneous tissue,piperacillin,penicillin,tazobactam,HPLC-UV,Scientist 2.0,2,NA,NA,NA,NA,no
https://dx.doi.org/10.1093/jac/dkp139,115,Roberts,2009,2009-01-01,Australia,High-income,High-income,prospective PK study,10,"known or suspected sepsis11 of a critically ill patient and normal renal function (defined as plasma creatinine concentration <120 µmol/L). Clinical indications for meropenem included nosocomial pneumonia, soft tissue infection, intra-abdominal sepsis and empirical therapy for sepsis without proven source",NA,no,unclear,sepsis,sepsis,NA,NA,NA,no,plasma,subcutaneous tissue,meropenem,carbapenem,no,HPLC-UV,NONMEM 6.1,2,"OFV, goodness-of-fit, bootstrapping, VPC",NA,"stepwise forward inclusion, backward elimination, OFV",Monte Carlo,yes
https://dx.doi.org/10.1016/j.ijantimicag.2009.10.008,116,Roberts,2010,2010-01-01,Australia,High-income,High-income,prospective randomised PK trial,16,patients admitted to the Critical Care Unit with known or suspected sepsis as defined previously [28] and with normal renal function (defined as plasma creatinine <120 μmol/L),NA,no,normal,sepsis,sepsis,NA,NA,NA,no,plasma,no,piperacillin,penicillin,tazobactam,HPLC-UV,NONMEM 6.1,2,"VPC, OFV, bootstrapping, goodness-of-fit",NA,Bayesian estimates,Monte Carlo,yes
https://dx.doi.org/10.1097/CCM.0b013e31826ab4c4,118,Roberts,2013,2013-01-01,International,High-income,High-income,retrospective PK study,31,Critically ill adult patients with nosocomial pneumonia and a clinical indication for doripenem were included,Patients with a known or suspected allergy to doripenem or carbapenem antibiotics were excluded,no,augmented,"pneumonia, ARC, obesity",pneumonia,ARC,obesity,NA,no,plasma,no,doripenem,carbapenem,no,LC-MS/MS,NONMEM 6.1,2,"OFV, visual inspection, goodness-of-fit, VPC, bootstrapping",NA,"stepwise forward inclusion, backward elimination, OFV",Monte Carlo,yes
https://dx.doi.org/10.1093/jac/dku177,119,Roberts,2014,2014-01-01,Australia,High-income,High-income,prospective PK study,12,Critically ill adult patients with AKI receiving CVVHDF and a clinical indication for doripenem,"Patients younger than 18 years or older than 90 years were excluded, as were pregnant patients or those with a known or suspected allergy to doripenem or carbapenem antibiotics",RRT,impaired,CRRT,CRRT,NA,NA,NA,no,plasma,"effluent, urine",doripenem,carbapenem,no,HPLC-MS/MS,S-ADAPT 1.57,2,"VPC, diagnostic plots, OFV, NPDE",NA,visual assessment,Monte Carlo,yes
https://dx.doi.org/10.1186/s13054-015-0818-8,120,Roberts,2015,2015-01-01,Australia,High-income,High-income,prospective PK study,24,"acute kidney injury (AKI) and at least one of the following: oliguria, hyperkalemia, severe acidemia (pH <7.2), an elevated plasma urea or creatinine concentration, or clinically significant organ edema",NA,RRT,impaired,CRRT,CRRT,NA,NA,NA,no,plasma,effluent,"meropenem, piperacillin",penicillin,"ciprofloxacin, tazobactam, vancomycin",LC-MS/MS,NONMEM 6.1,NA,goodness-of-fit,NA,NA,NA,yes
https://dx.doi.org/10.1093/jac/dku564,121,Roberts,2015,2015-01-01,Australia,High-income,High-income,prospective PK study,30,(i) age 18–80 years; and (ii) receiving cefazolin as prophylaxis for skin and soft tissue and bone infections after major trauma,(i) absence of intra-arterial catheter; (ii) pre-existing renal impairment (defined as a plasma creatinine concentration >171 μmol/L or the need for renal replacement therapy); or (iii) a history of allergy to cephalosporin antibiotics or iodine.,no,normal,trauma,trauma,NA,NA,NA,no,plasma,subcutaneous tissue,cefazolin,cephalosporin,no,HPLC,Pmetrics,3,"goodness-of-fit, VPC, LLR, bias, imprecision",biological plausibility,"LLR, goodness-of-fit",Monte Carlo,yes
https://dx.doi.org/10.1111/bcp.15487,122,Roelofsen,2023,2023-01-01,Netherlands,High-income,High-income,prospective PK study,92,≥18 years and admitted to the ICU with an expected stay of >72 hours,"written informed consent was not obtained, if admittance to the ICU was due to burn wounds, or if cefotaxime therapy was discontinued prior to sampling",no,unclear,general ICU,general ICU,NA,NA,NA,no,plasma,no,cefotaxime,cephalosporin,no,LC-MS/MS,NONMEM 7.4.2,2,"goodness-of-fit, VPC, NPDE",NA,"stepwise forward inclusion, backward elimination",Monte Carlo,yes
https://dx.doi.org/10.1093/jac/dkac245,123,Rohani,2022,2022-01-01,USA,High-income,High-income,retrospective PK study,70,"Critically ill patients with HAP admitted to the Medical ICU at Northwestern Memorial Hospital (Chicago, IL, USA) were enrolled between 30 June 2018 and 1 March 2021",NA,no,unclear,HAP,HAP,NA,NA,NA,no,plasma,no,meropenem,carbapenem,no,LC-MS/MS,Pmetrics 1.9.7,1,"goodness-of-fit, AIC",NA,NA,NA,yes
https://dx.doi.org/10.1093/jac/dkl349,124,Roos,2006,2006-01-01,Australia,High-income,High-income,retrospective PK study,13,Patients were enrolled if they had a serum creatinine concentration of <0.1 mmol/L,NA,no,normal,sepsis,sepsis,NA,NA,NA,no,plasma,no,cefepime,cephalosporin,no,HPLC,NONMEM 5,3,"OFV, goodness-of-fit, bootstrapping, VPC",NA,"stepwise forward inclusion, OFV",Monte Carlo,yes
https://dx.doi.org/10.1007/s00134-007-0573-7,125,Roos,2007,2007-01-01,Australia,High-income,High-income,prospective PK study,12,Twelve ICU patients received 2 g cefpirome every 12 h as a 3-min intravenous infusion. Patients were enrolled if they had serum creatinine concentration less than 0.1 mmol/l.,NA,no,normal,general ICU,general ICU,NA,NA,NA,no,plasma,no,cefpirome,cephalosporin,no,HPLC,NONMEM 5,3,"OFV, goodness-of-fit, bootstrapping, VPC",NA,"stepwise forward inclusion, OFV",Monte Carlo,yes
https://dx.doi.org/10.1128/AAC.01318-06,126,Sakka,2007,2007-01-01,Germany,High-income,High-income,prospective randomised PK trial,20,ICU-acquired pneumonia (duration of endotracheal intubation and mechanical ventilation of >3 days) and normal renal function,No patients with renal replacement therapy were enrolled,no,normal,VAP,VAP,NA,NA,NA,no,plasma,no,imipenem,carbapenem,no,LC-MS/MS,"Pmetrics, WinNonlin",2,"AIC, BIC, bias, precision",NA,general linear model,Monte Carlo,yes
https://dx.doi.org/10.3390/antibiotics11040434,127,Sanches,2022,2022-01-01,Brazil,Upper-middle-income,Middle-income,retrospective PK study,24,"aged >18 years, with a confirmed or suspected infection with indications for use of the antibiotic piperacillin/tazobactam","pregnant women, individuals positive for human immunodeficiency virus (HIV) or hepatitis B or C virus, patients with a known allergy to the piperacillin/tazobactam, patients who had previously been enrolled in this study, patients with serum creatinine >2 mg/dL or elevation superior to twice the baseline value",no,normal,general ICU,general ICU,NA,NA,NA,no,plasma,no,piperacillin,penicillin,tazobactam,HPLC-UV,Pmetrics 1.5.0,2,"likelihood ratio test, AIC, BIC",biological plausibility,"stepwise forward inclusion, -2LL, AIC, BIC",Monte Carlo,yes
https://dx.doi.org/10.3390/antibiotics11050618,128,Selig,2022,2022-01-01,USA,High-income,High-income,retrospective PK study,19,NA,NA,no,unclear,"trauma, burns",trauma,burns,NA,NA,no,plasma,no,piperacillin,penicillin,tazobactam,HPLC-UV,Pumas 1.1,2,"goodness-of-fit, bootstrapping, VPC",NA,"stepwise forward inclusion, OFV",Monte Carlo,yes
https://dx.doi.org/10.1111/bcp.15138,129,Selig,2022,2022-01-01,USA,High-income,High-income,retrospective PK study,23,NA,NA,RRT,impaired,burns,burns,NA,NA,NA,yes,plasma,effluent,meropenem,carbapenem,no,HPLC-UV,Pumas 1.05,2,"LRT, diagnostic plots, plausibility, goodness-of-fit, bootstrapping, VPC",NA,"stepwise forward inclusion, OFV",Monte Carlo,yes
https://dx.doi.org/10.1186/s13054-014-0565-2,131,Shekar,2014,2014-01-01,Australia,High-income,High-income,prospective PK study,11,Eligible patients ≥18 years of age and receiving meropenem during their ECMO therapy were recruited.,"Known allergy to study drug, pregnancy, serum bilurubin concentration >150 μmol/L, ongoing massive blood transfusion requirement (>50% blood volume transfused in the previous 8 hours) and therapeutic plasma exchange in the preceding 24 hours","ECMO, RRT",impaired,ECMO,ECMO,NA,NA,NA,no,plasma,no,meropenem,carbapenem,no,HPLC,NONMEM 7.3,2,"OFV, visual inspection",biological plausibility,stepwise forward inclusion and backward deletiom,Monte Carlo,yes
https://doi.org/10.2215/cjn.10260915,132,Shotwell,2016,2016-01-01,USA,High-income,High-income,prospective PK study,68,Patients ages 18 years old or older who were receiving piperacillin-tazobactam with concomitant CRRT in the ICU were included.,Patients were excluded if they were known to be pregnant.,RRT,impaired,CRRT,CRRT,NA,NA,NA,no,plasma,effluent,piperacillin,penicillin,tazobactam,HPLC,NLME,2,NLME regression,NA,Wald test,Monte Carlo,yes
https://dx.doi.org/10.1128/AAC.01265-19,133,Sime,2019,2019-01-01,Australia,High-income,High-income,prospective PK study,12,"ICU patients, aged ≥18 years, were enrolled if diagnosed with a systemic infection known or suspected to be caused by a bacterium susceptible to ceftolozane-tazobactam","Patients were excluded if they had renal dysfunction that necessitated the use of renal replacement therapy, had a known or suspected allergy to cephalosporins, had received piperacillin-tazobactam in the preceding 7 days, or were pregnant.",no,normal,ICU without renal impairment,general ICU,NA,NA,NA,no,plasma,no,ceftolozane,cephalosporin,tazobactam,UHPLC-MS/MS,Pmetrics 1.5.2,2,"LLR, AIC, BIC",biological plausibility as well as a preliminary regression analysis of each plausible cobvariate,"stepwise forward inclusion, backward elimination",Monte Carlo,yes
https://dx.doi.org/10.1128/AAC.01655-19,134,Sime,2020,2020-01-01,Australia,High-income,High-income,prospective PK study,6,Adult patients (≥18 years) admitted to RBWH ICU who were prescribed CRRT were enrolled if diagnosed with systemic infection known or suspected to be caused by an organism susceptible to ceftolozane-tazobactam.,Patients who were pregnant or had a documented or suspected allergy to penicillins and cephalosporin were excluded.,RRT,impaired,ICU patients receiving continuous venovenous hemodiafiltration,CRRT,NA,NA,NA,no,plasma,effluent,ceftolozane,cephalosporin,tazobactam,UHPLC-MS/MS,Pmetrics,4,"goodness-of-fit testing, LLR, AIC, BIC",biological plausibility,NA,Monte Carlo,yes
https://dx.doi.org/10.1128/AAC.01698-20,135,Sime,2021,2021-01-01,Australia,High-income,High-income,prospective PK study,10,Adult patients (≥18 years) admitted to the ICU were enrolled if they had an indwelling external ventricular drain (EVD) and informed consent was obtained.,"Patients were excluded if they had a history of allergy to penicillins and/or cephalosporins, they were receiving renal replacement therapy or had estimated creatinine clearance of <10 ml/min, and were receiving piperacillin-tazobactam or had received it in the 7 days before the time of screening.",no,normal,ICU patients with an indwelling external ventricular drain,EVD,NA,NA,NA,no,plasma,CSF,ceftolozane,cephalosporin,tazobactam,UHPLC-MS/MS,Pmetrics 1.5.2,3,"bias, imprecision, AIC, BIC, LLR",biological plausibility,regression analysis,Monte Carlo,yes
https://dx.doi.org/10.1089/sur.2018.141,136,Stein,2019,2019-01-01,USA,High-income,High-income,prospective PK study,10,Critically ill (Acute Physiology and Chronic Health Evaluation [APACHE] II score >10) adult patients being treated with CZA (ceftazidime/avibactem) were eligible to enroll into this study.,"Patients with a body mass index (BMI) >45 kg/m2, pregnancy, or with a creatinine clearance (CrCL) <30 mL/min were excluded.",no,normal,general ICU,general ICU,NA,NA,NA,no,serum,no,ceftazidime,cephalosporin,avibactam,LC-MS/MS,Pmetrics,1,"visual fit, AIC",NA,linear regression,Monte Carlo,yes
https://dx.doi.org/10.1002/phar.1324,137,Sturm,2014,2014-01-01,USA,High-income,High-income,prospective PK study,9,"Individuals were considered eligible for study inclusion if they were at least 18 years old, were admitted to the trauma-surgical intensive care service, had a BMI 40 kg/m2 or higher at the time of antimicrobial initiation, had piperacillin-tazobactam started for empiric or directed therapy as determined by their health care provider, and had available intravenous access.","Exclusion criteria for the study were a creatinine clearance 40 ml/minute or less, penicillin allergy, history of type I hypersensitivity reaction to any β-lactams, documented resistance to piperacillin-tazobactam, absolute neutrophil count less than 500/mm3, or physician refusal.",no,normal,"trauma, surgical ICU, obese",trauma,surgical ICU,obese,NA,no,serum,no,piperacillin,penicillin,tazobactam,HPLC,NA,1,NA,NA,NA,Monte Carlo,no
https://dx.doi.org/10.1007/s10928-019-09633-8,138,Sukarnjanaset,2019,2019-01-01,Thailand,Upper-middle-income,Middle-income,prospective PK study,48,"The inclusion criteria were (i) age ≥ 15 years, (ii) treatment with piperacillin/tazobactam, and (iii) sepsis defined according to the third international consensus definitions for sepsis and septic shock (Sepsis-3)","The exclusion criteria were (i) peritoneal dialysis, hemodialysis or continuous renal replacement therapy, (ii) pregnancy, (iii) sepsis more than 24 h and (iv) known or suspected hypersensitivity to piperacillin/tazobactam.",no,normal,general ICU,general ICU,NA,NA,NA,no,plasma,no,piperacillin,penicillin,tazobactam,HPLC,NONMEM 7.4.1,2,"visual fit, bootstrapping, VPC",NA,stepwise approach,Monte Carlo,yes
https://dx.doi.org/10.1007/s00228-021-03218-6,139,Swartling,2022,2022-01-01,Sweden,High-income,High-income,prospective PK study,51,Patients above the age of 18 years admitted to the ICUs and treated with cefotaxime for a proven or suspected infection were included in the study. Patients were included within 24 h from initiation of cefotaxime treatment.,"Pregnant patients and patients with treatment restrictions were excluded in the study. Additionally, patients on renal replacement therapy were excluded in this current analysis.",no,normal,"general ICU, burns",burns,NA,NA,NA,no,serum,no,cefotaxime,cephalosporin,no,LC-MS/MS,NONMEM 7.4,2,"OFV, LLR, goodness-of-fit, bootstrapping, VPC",clinically available covariates,stepwise forward inclusion and backward elimination,NA,yes
https://dx.doi.org/10.1002/jcph.432,140,Tamme,2015,2015-01-01,Estonia,High-income,High-income,prospective PK study,9,"severe sepsis or septic shock as defined by the ACCP/SCC Consensus Conference, with acute kidney injury (AKI) deemed by the treating clinician to require HVHDF, based on the presence of at least one of the following criteria: (1) oliguria (urine output <100 mL in a 6-hour period), unresponsive to fluid therapy, (2) serum potassium concentration exceeding 6.5 mEq/L, (3) severe acidemia (pH <7.2), (4) plasma urea nitrogen level above 70 mg/dL, (5) serum creatinine concentration above 3.4 mg/dL, or (6) presence of clinically significant organ edema (eg, pulmonary edema), and had an arterial line in situ","known hypersensitivity to carbapenems or other beta-lactams, pregnancy, and life expectancy of less than 8 hours",RRT,impaired,"CRRT, septic shock",CRRT,septic shock,NA,NA,no,plasma,no,doripenem,carbapenem,no,UHPLC-MS/MS,NONMEM 7.3.0,2,"goodness-of-fit, OFV, bootstrapping",biological plausibility,OFV,Monte Carlo,yes
https://dx.doi.org/10.1128/aac.41.12.2640,141,Tegeder,1997,1997-01-01,Germany,High-income,High-income,prospective PK study,12,"Thirteen consecutive patients who were admitted to the surgical intensive care unit, who were treated with CVVH for ARF, and who were receiving imipenem-cilastatin for the treatment of a severe life-threatening infection were enrolled in this  study",NA,RRT,impaired,CRRT,CRRT,NA,NA,NA,no,plasma,haemofiltrate,imipenem,carbapenem,no,HPLC,Topfit,2,"AIC, Imbimbo information criterion",NA,NA,simulations,no
https://dx.doi.org/10.1016/S0009-9236%2899%2970121-9,142,Tegeder,1999,1999-01-01,Germany,High-income,High-income,prospective PK study,9,patients of the surgical intensive care unitwith severe life-threatening infections and acute renal fail-ure were enrolled in this study provided they were treated with meropenem and undergoing continuous venovenous hemofiltration,Two patients were excluded: one because of interfering chromatographic peaks that made a reliable determination of plasma concentrations impossible; the other had polyuric acute renal failure with a residual creatinine clearance of approximately 24 mL/min and therefore somewhat different pharmacokinetic data,RRT,impaired,CRRT,CRRT,NA,NA,NA,no,plasma,haemofiltrate,meropenem,carbapenem,no,HPLC,Micromath Scientist,2,NA,NA,NA,simulations,no
https://dx.doi.org/10.29090/psa.2018.04.017.0042,143,Thuy,2018,2018-01-01,Vietnam,Lower-middle-income,Middle-income,prospective PK study,30,Patients admitted to ICU or general medicine department,"allergic to meropenem, <18 years old, pregnant or breastfeeding or on dialysis",no,normal,"general ICU, pneumonia",pneumonia,NA,NA,NA,no,plasma,no,meropenem,carbapenem,no,HPLC,Monolix 2016,2,"AIC, BIC, goodness-of-fit, VPC",NA,"stepwise forward inclusion, backward elimination, OFV",NA,yes
https://dx.doi.org/10.1128/aac.00321-22,144,Truong,2022,2022-01-01,Vietnam,Lower-middle-income,Middle-income,prospective PK study,27,"aged ≥18 years with meropenem administration, ICU stay of >24 h, and a urine catheter in situ","receiving RRT, plasma exchange, or ECMO prior to study enrollment",no,normal,general ICU,general ICU,NA,NA,NA,no,plasma,no,meropenem,carbapenem,no,HPLC-UV,Pmetrics,1,"goodness-of-fit, bias, precision, VPC, bootstrapping",clinical plausibility,"stepwise forward inclusion, backward elimination, LLR",Monte Carlo,yes
https://doi.org/10.1128/aac.01657-16,145,Tsai,2016,2016-01-01,Australia,High-income,High-income,prospective PK study,9,(i) Australian Indigenous; (ii) ≥18 years of age; (iii) confirmed or suspected severe sepsis within the previous 48 h; (iv) prescribed meropenem; and (v) an arterial line in situ,(i) creatinine clearance (CLCr) <15 mL/min; (ii) requiring haemodialysis or continuous renal replacement therapy; and (iii) pregnancy,no,normal,sepsis,sepsis,NA,NA,NA,no,plasma,no,piperacillin,penicillin,tazobactam,UHPLC-MS/MS,Pmetrics,2,"goodness-of-fit, coefficient of determination, bias, imprecision, VPC",NA,"LLR, goodness-of-fit",NA,yes
https://dx.doi.org/10.1016/j.ijantimicag.2016.08.015,146,Tsai,2016,2016-01-01,Australia,High-income,High-income,prospective PK study,11,(i) Australian Indigenous; (ii) ≥18 years of age; (iii) confirmed or suspected severe sepsis within the previous 48 h; (iv) prescribed meropenem; and (v) an arterial line in situ,(i) creatinine clearance (CLCr) <15 mL/min; (ii) requiring haemodialysis or continuous renal replacement therapy; and (iii) pregnancy,no,normal,sepsis,sepsis,NA,NA,NA,no,plasma,no,meropenem,carbapenem,no,HPLC-UV,Pmetrics,2,"goodness-of-fit, coefficient of determination, bias, imprecision",NA,"LLR, Goodness-of-fit",Monte Carlo,yes
https://dx.doi.org/10.1186/s13054-015-0750-y,147,Udy,2015,2015-01-01,Australia,High-income,High-income,prospective PK study,48,between 18 and 80 years of age and were receiving piperacillin-tazobactam for the treatment of sepsis (defined as presumed or confirmed nosocomial infection while manifesting a systemic inflammatory response syndrome),"(1) did not have an intraarterial line inserted as part of routine management (to allow repeated plasma sampling without additional venipuncture), (2) had renal impairment (defined by a plasma creatinine concentration (CR) greater than 171 μmol/L or the need for renal replacement therapy) or (3) had a history of allergy to piperacillin or iodine",no,normal,sepsis,sepsis,NA,NA,NA,no,plasma,no,piperacillin,penicillin,no,HPLC-UV,NONMEM 7.1,2,"LLR, OFV, goodness-of-fit, bootstrapping",NA,NA,Monte Carlo,yes
https://dx.doi.org/10.1093/jac/dkq184,148,Ulldemolins,2010,2010-01-01,Australia,High-income,High-income,prospective PK study,10,"age between 18 and 80 years old, known or suspected infection produced by MSSA, hypoalbuminaemia arbitrarily defined as albumin plasma levels ≤32 g/L",severe renal dysfunction arbitrarily defined as plasma creatinine concentration <170 µmol/L,no,normal,"hypoalbuminaemia, sepsis",hypoalbuminaemia,sepsis,NA,NA,no,plasma,urine,flucloxacillin,penicillin,no,HPLC-UV,NONMEM 6.1,2,"OFV, goodness-of-fit, bootstrapping",NA,"stepwise forward inclusion, OFV",Monte Carlo,yes
https://dx.doi.org/10.1128/AAC.00712-15,149,Ulldemolins,2015,2015-01-01,Spain,High-income,High-income,prospective PK study,30,"age of ≥18 years, a diagnosis of septic shock by the criteria of the Surviving Sepsis Campaign guidelines, CRRT, and an indication for treatment with meropenem",severe chronic kidney disease requiring RRT,RRT,impaired,"septic shock, CRRT",septic shock,CRRT,NA,NA,no,plasma,no,meropenem,carbapenem,no,LC-MS/MS,NONMEM 7.3,1,"VPC, bootstrapping, bias, imprecision, goodness-of-fit, LLR",biological plausibility,"stepwise forward inclusion, LLR, Bayesian shrinkage",Monte Carlo,yes
https://dx.doi.org/10.1093/jac/dkv503,150,Ulldemolins,2016,2016-01-01,Spain,High-income,High-income,prospective PK study,19,"age ≥18 years, MODS including septic shock diagnosed by the Surviving Sepsis Campaign guidelines criteria,11 AKI requiring CVVHDF and clinical indication for piperacillin",chronic renal disease requiring dialysis,RRT,impaired,"MODS, CRRT",MODS,CRRT,NA,NA,no,plasma,no,piperacillin,penicillin,tazobactam,LC-MS/MS,NONMEM 7.3,2,"goodness-of-fit, LLR, OFV, Bayesian estimates, precision, observed concentrations, VPC, bootstrapping",biological plausibility,"stepwise forward inclusion, OFV, Bayesian shrinkage",Monte Carlo,yes
https://dx.doi.org/10.1007/s00228-021-03100-5,151,Ulldemolins,2021,2021-01-01,Spain,High-income,High-income,prospective PK study,8,"Inclusion criteria were age ≥18 years, septic shock diagnosed by the Surviving Sepsis Campaign guidelines criteria, AKI requiring CVVHDF, and clinical indication for ceftriaxone.",The major exclusion criterion was chronic renal disease requiring intermittent chronic dialysis,RRT,impaired,"sepsis, hypoalbuminaemia, CRRT",sepsis,hypoalbuminaemia,CRRT,NA,no,plasma,no,ceftriaxone,cephalosporin,no,LC-MS/MS,NONMEM 7.3,2,"goodness-of-fit, OFV, AIC, BIC, bootstrap resampling, VPC",biological plausibility,cumulative forward inclusion/backward elimination,Monte Carlo,yes
https://doi.org/10.1007/bf00542421,152,Van Dalen,1986,1986-01-01,Netherlands,High-income,High-income,prospective PK study,20,"All patients were on mechanical ventilation in the Intensive Care Department. After informed consent had been obtained, 20 patients were selected for the study",NA,RRT,impaired,"heart failure, septic shock, hypovolaemia",heart failure,septic shock,hypovolaemia,NA,no,serum,urine,ceftazidime,cephalosporin,no,HPLC,NON-LIN,2,NA,NA,NA,NA,no
https://dx.doi.org/10.1007/BF01960743,153,Van Dalen,1987,1987-01-01,Netherlands,High-income,High-income,prospective PK study,64,adults on mechanical ventilation in the intensive-care department,NA,RRT,impaired,"heart failure, septic shock, hypovolaemia",heart failure,septic shock,hypovolaemia,NA,no,serum,urine,"cefoxitin, cefuroxime, ceftazidime, ceftriaxone",cephalosporin,no,HPLC,NON-LIN,2,NA,NA,NA,NA,no
https://doi.org/10.1007/s001340050424,154,van der Werf,1997,1997-01-01,Netherlands,High-income,High-income,prospective PK study,9,"aged over 18 years with anuric renal failure, requiring CVVH and in need of antimicrobial treatment including the covering of gram-negative pathogens, as judged by the attending physician, were selected by the investigators among patients admitted to our Intensive Care Unit (ICU) with the consent of the responsible physician","any evidence for contraindication, e. g., idiosyncrasy, allergy or other intolerance for the study medication or any other beta-lactam antibiotic agent",RRT,impaired,"general ICU, CRRT",CRRT,NA,NA,NA,no,serum,no,piperacillin,penicillin,tazobactam,HPLC,KINFIT,2,NA,NA,NA,NA,no
https://dx.doi.org/10.1128/AAC.01801-15,156,Vossen,2015,2015-01-01,Austria,High-income,High-income,prospective PK study,14,Only sedated and intubated patients 18 years old or older and in need of intensive care unit (ICU) treatment and renal replacement therapy were deemed eligible,Exclusion criteria included a urine production of >500 ml/24 h and therapy with probenecid or valproic acid,RRT,impaired,CRRT,CRRT,NA,NA,NA,no,plasma,effluent,doripenem,carbapenem,no,HPLC-UV,NONMEM 7.3,2,"OFV, goodness-of-fit, VPC",NA,"stepwise forward inclusion, backward elimination",Monte Carlo,yes
https://dx.doi.org/10.1093/jac/dkab314,157,Wallenburg,2021,2021-01-01,Netherlands,High-income,High-income,prospective PK study,33,Patients admitted to the ICU who were treated with flucloxacillin IV therapy were eligible for inclusion if they were ≥18 years of age and if they were managed with a central venous or arterial catheter to facilitate blood sampling,NA,RRT,impaired,general ICU,general ICU,NA,NA,NA,no,plasma,no,flucloxacillin,penicillin,no,LC-MS/MS,NONMEM 7.4.1,2,"OFV, goodness-of-fit",physiological plausibility,OFV,Monte Carlo,yes
https://dx.doi.org/10.1007/s40262-022-01113-6,158,Wallenburg,2022,2022-01-01,Netherlands,High-income,High-income,prospective PK study,39,"All patients admitted to the ICU who were treated with intravenous piperacillin–tazobactam as part of routine clinical care were eligible for inclusion if they were ≥ 18 years of age, started piperacillin–tazobactam therapy ≤ 72 h before inclusion, and were managed with a central venous and/or arterial catheter",renal replacement therapy or extracorporeal membrane oxygenation,no,normal,general ICU,general ICU,NA,NA,NA,no,plasma,urine,piperacillin,penicillin,tazobactam,UPLC-MS/MS,NONMEM 7.4.1,2,"OFV, goodness-of-fit, AIC",physiological plausibility,"OFV, AIC",Monte Carlo,yes
https://dx.doi.org/10.1111/bcp.14846,159,Westermann,2021,2021-01-01,Germany,High-income,High-income,prospective PK study,25,Patients aged ≥18 years with sepsis treated with meropenem were eligible for study enrolment,NA,RRT,impaired,"CRRT, sepsis",CRRT,sepsis,NA,NA,no,plasma,no,meropenem,carbapenem,no,LC-MS/MS,NONMEM 7.4,1,"LLR, OFV, AIC, goodness-of-fit, VPC, bootstrapping",biological plausibility,"stepwise forward inclusion, backward elimination",Monte Carlo,yes
https://dx.doi.org/10.1093/jac/40.2.269,160,Young,1997,1997-01-01,China,Upper-middle-income,Middle-income,prospective PK study,10,adult patients in the Intensive Care Unit who required ceftazidime according to usual clinical practice were enrolled,"history of allergy to cephalosporins, renal impairment (as defined by a serum creatinine concentration of 120 mol/L) or were already receiving ceftazidime",no,normal,pneumonia,pneumonia,NA,NA,NA,no,plasma,no,ceftazidime,cephalosporin,no,HPLC,MK MODEL 5.02,2,NA,NA,multiple regression analysis,NA,yes
https://dx.doi.org/10.3390/pharmaceutics14122786,161,Zahr,2022,2022-01-01,France,High-income,High-income,retrospective PK study,55,hospitalized in the intensive care units (ICU) at Pitié-Salpêtrière hospital. Patients were treated by cefiderocol in combination with other antibiotics for ventilator-associated bacterial pneumonia (VABP),NA,no,unclear,VAP,VAP,NA,NA,NA,no,plasma,no,cefiderocol,cephalosporin,no,UPLC-MS/MS,Monolix 2020R1,2,"BIC, VPC, goodness-of-fit, NPDE",NA,NA,NA,yes
https://dx.doi.org/10.1007/s40121-021-00551-2,162,Zhao,2022,2022-01-01,China,Upper-middle-income,Middle-income,prospective PK study,64,"(1) patients admitted to the Department of Respiratory and Critical Care Medicine in our hospital with a diagnosis of pneumonia; (2) use of meropenem empirically or therapeutically; (3) time of continuous medication > 2 days; (4) at least one steady-state plasma concentration could be obtained; (5) age > 18 years, and (6) gram-negative bacteria were isolated from specimen culture if possible",(1) pregnancy and lactation; (2) allergy to carbapenems; (3) concomitant uses of sodium valproate; (4) incomplete dosing information or clinical data,no,unclear,pneumonia,pneumonia,NA,NA,NA,no,blood,no,meropenem,carbapenem,no,HPLC,Phoenix NLME 8.1,2,"VPC, goodness-of-fit, OFV",NA,OFV,Monte Carlo,yes
https://doi.org/10.1128/aac.01347-15,163,Öbrink-Hansen,2015,2015-01-01,Denmark,High-income,High-income,prospective PK study,15,Critically ill patients with known or suspected septic shock who required noradrenaline infusion and who were prescribed piperacillin-tazobactam (4 g/0.5 g) (Tazocin) by the treating physician were eligible for the study. All patients had an arterial catheter.,Patients on renal replacement therapy and patients under the age of 18 years were excluded.,no,normal,septic shock,septic shock,NA,NA,NA,no,plasma,no,piperacillin,penicillin,tazobactam,UHPLC,NONMEM 7.2,2,"goodness-of-fit, VPC, OFV",NA,"stepwise forward inclusion, backward elimination, OFV",Monte Carlo,yes
